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Childhood chronic kidney disease (CKD) is a devastating illness requiring life-long 
medical input, often progressing to end stage kidney disease (ESKD) requiring dialysis 
and renal transplantation. Despite an increasing number of children now surviving 
through childhood and early adulthood, heart disease remains one of the major causes 
of death in individuals with childhood-onset CKD as young adults and it is likely this 
relates to onset of pre-clinical cardiovascular disease developing during childhood.  
Arterial stiffening relates to the severity of CKD, being greatest in those with dialysis 
dependent CKD, and is thought to be driven, at least in part, by excess body weight, 
hypertension and metabolic changes associated with CKD but their contribution to 
arterial disease progression remains poorly understood.  
The relationship of blood pressure with arterial disease remains unclear in the paediatric 
literature. Previous studies performed in children pre-dialysis, those on dialysis and 
following kidney transplantation have measured pulse wave velocity (PWV) of the 
carotid-femoral pathway (i.e. mainly the aorta) and/or measures of carotid mechanics 
have been examined but these studies have been limited by lack of concurrent 
measures of carotid blood pressure (required to determine functional elasticity of the 
carotid artery). Furthermore, whilst the potential impact of age and blood pressure (BP) 
have been adjusted for, when comparing differences between children with and without 




The objectives of my thesis are to 1) to determine the use of an easy to perform, well 
tolerated technique to measure PWV in children. 2) to compare estimates of central 
aortic systolic pressure with that measured directly from catheter placed in the aortic 
root. 3) to determine typical estimates of systolic blood pressure amplification and 4) to 
determine the association of arterial function and structure with severity of childhood 
CKD and to examine the relation of these measures to blood pressure. 5) to design a 
controlled trial to evaluate effects of aggressive versus standard blood pressure control 
on cardiovascular target organ damage. 
My research findings report novel data relating to my project objectives. We compared 
two different techniques to measure PWV (volumetric and tonometric) and observed 
that the volumetric technique is easy to perform, well tolerated and reproducible when 
measurements are made by the same observer consecutively, but that the results are of 
the two techniques are not inter-changeable. My work for objective 2 and 3 measured 
central blood pressure at the aortic root at the time of arterial cannulation and confirmed 
that blood pressure measured in the arm differs from that close to the heart. We 
validated simple non-invasive methods to measure blood pressure in children and 
showed that peripheral systolic amplification is substantial, including those with and 
without hypertension and mild to advanced CKD, with a mean amplification of ~ 20 
mmHg and thus may be relatively more important than in adults. In a cohort of children 
with and without CKD, we performed a comprehensive characterization of arterial 
biomechanics and observed that the changes in elastic properties of the carotid artery 
were related to increased blood pressure, and not to decreased glomerular filtration 
rate. Important limitations to this cross-sectional study include lack of knowledge of 
17 
 
duration of both hypertension and CKD and lack of formal sample size calculation. 
Despite these limitations the results from my thesis suggest that blood pressure 
reduction may be an effective means to protect against arterial stiffening and needs to 
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1.1.  Scale of the problem- CKD during childhood 
 
Chronic kidney disease (CKD) is a major public health issue with an estimated 6-16% of 
the adult populations surveyed in the developed world affected.1-4 Both pre-dialysis CKD 
and established renal failure (ERF) or end stage kidney disease (ESKD) requiring 
dialysis and transplantation have rapidly increased over the last two decades.2-5  
Although children with ERF account for a fraction of the total ERF patient population it is 
a devastating illness during childhood, with a profound impact on the child and their 
family.6 CKD is one of the commonest chronic illnesses of childhood that leads to 
lifelong health needs including future need for organ transplantation.7  
Population based studies in children including both predialysis and dialysis cohorts, 
report an incidence of 7.5-12.1 and prevalence of 29.4-74.7 cases per year per million 
in children <18 years of age.6,8-10 In the United Kingdom, the incidence and prevalence 
rates of children with ERF for the UK has remained stable and was 9.3 and 58.2 per 
million children <16 years of age.11 At any time there are about 150-200 children with 
ERF requiring regular dialysis in the United Kingdom, with 50-70 new patients 
commencing dialysis each year.11 The number of children with moderate to severe CKD 
being treated in specialist paediatric nephrology units in the UK is not known but is 
estimated to be 5-10 times more than the prevalent ERF population.  
We recently reported the incidence and prevalence of children with predialysis stages 3-
5 of CKD at our tertiary Paediatric Nephrology centre at the Evelina London Children’s 
Hospital (ELCH) serving the South East England.12 The mean incidence and prevalence 
29 
 
of children <16 years during the 5-year study period was 17.5 and 90.0 per million age-
related population (pmarp), respectively. We reported a marked increase in incidence 
and prevalence over the 5 year study period (incidence 8.4 to 25.2 pmarp; prevalence 
79.5 to 104.7 pmarp) [Figure 1].12  
 
Figure 1: Annual incidence and prevalence rate in children with stages 3-5 of CKD over 
the 5 year period 2005-2009 in the South East of England 
 
 
In this cohort, there were 288 children (58% males) with median (IQR) age of 6.7 (2.3, 
12.1) years and nearly 60% of prevalent cases secondary to congenital anomalies of 
the kidney and urinary tract (CAKUT), and only 17% secondary to an underlying 
glomerular disease12, in keeping with other published paediatric reports.6 















































1.2. Definitions and stages of chronic kidney disease 
Renal function or glomerular function rate (GFR) can be measured accurately using a 
‘formal’ measure of renal function or estimated from the plasma creatinine using 
validated equations and is expressed in ‘ml/min/1.73m2’. The most widely accepted 
method for estimating renal function in children is by the Schwartz formula13, with recent 
modifications to the equation suggested as a result of improvement in the techniques to 
measure plasma creatinine.12,14,15 In children, as in adults CKD is categorised based on 
increasing severity of renal dysfunction (Table 1).16,17 
 
Table 1: Classification of chronic kidney disease in children from the National Kidney 
Foundation’s Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) stages of 
chronic kidney disease16,17 
CKD Stage Clinical state GFR in ml/min/1.73m
2
 
1 Kidney damage with normal or increased GFR >90 
2 Kidney damage with mild decrease in GFR 60-89 
3a Moderate decrease in GFR (early) 45-59 
3b Moderate decrease in GFR (late) 30-44 
4 Severe decrease in GFR 15-29 
5 End Stage Renal Disease requiring renal replacement 
therapy 
<15 or dialysis 
 
1.3. Cardiovascular mortality and morbidity in CKD 
Cardiovascular (CV) disease in adult patients with CKD is highly prevalent with a 10-30 
fold increase in mortality in patients on dialysis when compared with age matched 
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individuals from the general population.18,19 Adult patients with predialysis CKD also 
have very high rates of mortality secondary to CV disease that presents even before 
onset of ERF.17,20,21  
The risk of cardiac death is increased almost 700 times in young adults with ERF when 
compared with age-matched healthy peers.22 With modern management and 
advancements in dialysis therapy, increasing number of children now survive through 
childhood to early adulthood but as young adults continue to exhibit an increased risk of 
mortality when compared with age-matched healthy peers. Young adults with childhood-
onset  ERF, exhibit mortality rates about 30 fold higher than children with no renal 
disease and a cardiac cause for death in them accounts for 40-45% of all mortality.19,23 
Recent data with extended follow-up of those with childhood-onset  ERF from Northern 
Europe, now aged 30-50 years old shows a reduction in cardiovascular related deaths 
and an increase in infection related deaths.24 Overall, though, moderate to severe renal 
disease results in a markedly reduced life expectancy for children on dialysis by 40-60 
years and by 20-25 years for children who have received a kidney transplant when 
compared with age, gender and race matched individuals with no renal disease from the 
general population.19,22,25 Although cardiac disease accounts for a fraction of mortality in 
the general childhood population, for children with ESKD on dialysis CV disease during 
childhood accounts for 28-32% of mortality25-28 , with little improvement in mortality, at 
22%, secondary to cardiac causes following renal transplantation.25,26 During childhood 
the risk of death remains the highest in the youngest children on haemodialysis.11,29,30   
Table 2 extended from a review by Lillien et al31, outlines key studies that have provided 
medium to long term CV outcomes in children with chronic kidney disease.19,23,24,26,28-
32 
 
30,32 It is important to note that these studies provide minimal data regarding several risk 
factors of interest such as blood pressure levels or indices of calcium-phosphate 














Table 2: Key reports in children with chronic kidney disease that have provided medium to long term cardiovascular 
outcomes in children 
Study Setting 
Number of pts (Number of 
deaths) 
Duration of F/U 










National Registry  
 
Era 1962-2002 




45 % cardiovascular deaths (57% 
in haemodialysis patients versus 
30% in renal transplant recipients  
 
Median of 9.7 years 25% cardiac arrest; 14% 
myocardial ischaemia ; 
11% pulmonary oedema 
and 22% other 
cardiovascular causes 
 
Young age at time of 
commencement of RRT; 
treatment with dialysis. 
 
Parekh et al




n=1380 deaths of which 22.5% 
deaths (311 deaths) were 
cardiovascular deaths (highest in 
haemodialysis patients 48.9% 
versus 23% in renal transplants) 
 
 
Analysis of deaths in 
<30 year olds who 
commenced RRT 
aged <20 years 
between 1990-1996 
52% cardiac arrest; 16% 
cardiomyopathy; 14% 
arrhythmia; 7% myocardial 
infarction   
Aged 20-30 years; 
haemodialysis and Black 
patient ethnicity at highest 
risk of death 
Chavers et al




n=1454 with 31.1% deaths cardiac 
deaths (452 deaths)  
 
5-10 years 20% arrhythmia; 12% 
valvular heart disease; 
10% cardiomyopathy; 6% 
cardiac arrest/death 
Older adolescents, Black 
ethnicity and female at 




Number of pts (Number of 
deaths) 
Duration of F/U 









registry report  but 
with case note 
review 
 
LERIC cohort  
(<15 year born 
before 1979 and 
commenced  RRT  
1972-1992) 
 
n=249 with 25.3% deaths (63 
deaths) 
41% cardiovascular deaths 
 
SMR 31 
Average f/u 15.5 
years  
58% cerebro-vascular 
accidents; 15% CHF; 12% 
myocardial iscaemia; 8% 
cardiac arrest  
Commencement of RRT at 
young age; long dialysis 
period and prolonged 
untreated hypertension had 
higher mortality secondary 
to CVA 
Oh et al
32 Single center  data  
 
Era 1970-1997 
n=283 with  14.8% deaths (42 
deaths) 




More than 15 years Not reported 49 patients lost to follow- 
up; 
No discussion regarding 
cause of death 
Samuel et al
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n=843 with 12.7% deaths (n=107) 
in <18 year olds.  
 
22% (n=23) were cardiovascular 
deaths 
median f/u 6.8 (3.0, 
10.6) years 
4% hyperkalemia; 4%  
myocardial 
iscaemia/infarction; 4% 
cardiac failure; 1% fluid 
overload and 9% cardiac 
arrest, cause unknown) 
No significant improvement 






Number of pts (Number of 
deaths) 
Duration of F/U 












n=23401 with 12.7% deaths 
(n=2975) in <21 year olds. <5year 
olds at ESKD initiation n=705 
deaths (20.4%). 36.9% (n=1098) 
were cardiovascular deaths 
 
 
Analysis of deaths in 









LERIC cohort  
(<15 year born 
before 1979 and 




up and report on 
mortality, and 





n=249 with 39% deaths (97 
deaths) 
 
62% cardiovascular related 
deaths 
 
Cardiovascular mortality rate 
(deaths per 100 patient years) 
reduced 




CV mortality rate: 
1972-89: 0.97  
1990-99: 0.37  




myocardial iscaemia; 9% 
other (congestive heart 
failure, cardiac arrest, 
pericarditis, aorta 
dissection)  
Highlighted a reduction in 
the rates of cardiovascular 
mortality when compared 
with previous era of follow 
up 




1.4. Causes of cardiovascular deaths in children with CKD 
The cause of cardiovascular deaths in young adults with childhood onset CKD is often 
secondary to sudden cardiac death or ‘cardiac arrest’, and account for 6-52% of cases 
excluding cases secondary to hyperkalemia or cerebrovascular events.24,29-31 Fatal 
arrhythmia, cardiomyopathy or valvular disease are next most common, with a smaller 
proportion of patients with ischaemic heart disease.19,23-26,28,30 This large variation in the 
prevalence rate of ‘cardiac arrest’ in reported series probably reflects the difficulties in 
establishing the correct diagnosis particularly in younger children.29,31 In adult patients 
with ERF sudden cardiac death is also a major cause of death and is seen more often 
than in adults with no renal disease in whom coronary artery disease and heart failure 
are the commonest causes of cardiac death.33,34 Fatal arrhythmia presenting as sudden 
cardiac death and the risk factors for these in adult patients on dialysis are now 
increasingly being recognised.34,35 In children on dialysis it is likely that a number of 
these risk factors are prevalent and include abnormal hemodynamic and biochemical 
factors, rapid changes during dialysis in both hemodynamic and biochemical factors, 
autonomic dysfunction and ischaemic damage to the myocardium.  
Following kidney transplantation although renal function improves it by no means 
becomes normal. Restoration of renal function by transplantation reduces though does 
not eliminate this increased CV risk and CV disease as a cause of mortality remains 





1.5. Cardiovascular risk factors in CKD  
Most experts categorise cardiovascular risk factors in patients (both adult and children) 
with CKD as either traditional or non-traditional (Table 3).18,36 Traditional risk factors are 
similar to those from the Framingham Heart Study that have been used to estimate the 
risk of developing symptomatic ischemic heart disease.37,38 As patients with CKD have 
several additional risk factors for CV disease, non-traditional risk factors have been 
proposed.  
 
Table 3: ‘Traditional’ and ‘non-traditional’ risk factors for cardiovascular disease in 







Dyslipidaemia (↑LDL, ↓ HDL) 
Tobacco use 
Physical inactivity 
Left ventricular hypertrophy 










CKD related dydlipidaemia [↑LDL, ↓ HDL, ↑TG, ↑Lp(a)] with altered 
structure and delayed metabolism of lipids 
Oxidative stress (e.g. reduced nitric oxide balance) 
Thrombogenic factors 
LDL, low-density lipoprotein; HDL, high density lipoprotein; TG, triglycerides; Lp(a) lipoprotein a. Modified 




Sarnak et al18, defined a non- traditional risk factor as one that should ideally meet all 
the following four criteria:  
(i) biological plausibility as to why the factor should promote CV disease risk;  
(ii) demonstration that the risk factor increases with worsening renal function;  
(iii) demonstration of an association between the risk factors and CV disease in 
CKD in observational studies; and  
(iv) demonstration in placebo-controlled clinical trials that treatment of the risk 
factor decreases CV disease outcomes.   
CV risk factors for adult CKD patients are shown in Table 3. Following transplantation 
several of these risk factors remain (e.g. hypertension, LVH, obesity, dyslipidaemia and 
abnormal calcium-phosphate metabolism), some new risk factors such as diabetes 
emerge and some CV risk factors such as hypertension and obesity get amplified. 
Table 4 highlights published data regarding CV risk factors in children with predialysis 
and dialysis dependent CKD. It is important to highlight here that in children, the 
majority of non-traditional risk factors listed in Table 3 satisfy the first two criteria with 
few risk factors satisfying criteria 3 and none criteria 4, as defined by Sarnak et al.18  
Risk factors may be modifiable and thus could be a target of clinical management to 
improve clinical outcomes. The modifiable risk factors proposed in children include 
prevention of malnutrition and appropriate management of anemia, insufficient blood 
pressure control, dyslipidemia, disorders of calcium-phosphate metabolism such as 
increased phosphate, high intake of calcium salts or active vitamin D and high serum 
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levels of intact parathyroid hormone.31 Indeed it has been suggested that the observed 
reduction in mortality in children and young adults with ERF, when compared with 
historic data may be secondary to improvement in achievement of treatment targets and 
pathways.24,25  
 
Table 4: Cardiovascular risk factors in children with CKD for which there is published 
evidence 
Risk factor Predialysis CKD Dialysis dependent CKD 













































































A complex issue in this multi-factorial relationship between cardiovascular disease and 
CKD has been to tease out the individual role of particular CV risk factors in a typical 
adult patient with CKD. This is because of the over-representation of traditional risk 
factors in adult patients. A typical adult patient with ERF on dialysis has diabetes or 
atherosclerosis as the primary cause of ERF, and in whom heart disease including 
hypertension often antedates onset of renal disease.75 Children with CKD on the other 
hand offer a unique opportunity to investigate CV risk factors in the absence of 
significant co-morbidities such as diabetes, atherosclerosis, smoking and ischemic heart 
disease.  
There is an increasing prevalence of risk factors with worsening stages of CKD although 
these data are indicative of association only. Further, several key questions regarding 
the role of CV risk factors in paediatric CKD remain unanswered and include (i) lack of 
clear evidence for the level of GFR beyond which cardiovascular risk begins in children; 
(ii) if both traditional and non-traditional risk factors are real CV risk factors in children in 
the earlier stages of CKD; (iii) if primary disease causing CKD has different CV risk 
factor profiles; (iv) are there some mechanisms unique to children that dictate the 
relationship between these CV risk factors and CKD; (v) what is the cause of the very 
high rate of ‘cardiac arrest’ and sudden cardiac death observed in children, in particular 
the youngest children; and (vi) if control of some key risk factors such as blood pressure 





1.6. Pathophysiological mechanisms 
Cardiac and arterial disease is thought to result from the cumulative effects of numerous 
risk factors. Pathophysiological mechanisms include endothelial dysfunction, 
atherosclerosis, arterial stiffening or arteriosclerosis, left ventricular hypertrophy (LVH) 
and myocardial fibrosis.18 It is likely that these evolve in parallel and worsen over time, 
with a likely significant adverse impact of increasing duration of moderate to severe 
CKD and worsening GFR.73  
1.6.1. Endothelial dysfunction: 
The healthy endothelium acts to maintain blood fluidity, protect the arterial wall from 
invasion by circulating monocytes and regulates vascular tone.77,78 Nitric oxide (NO) 
derived from endothelial nitric oxide synthase (eNOS) in response to shear stress on 
the endothelium generated from blood flow regulates vascular tone and has a number 
of anti-atherogenic actions. eNOS function has thus received much attention both in it’s 
own right and as a marker of more generalised endothelial function.77 It is usually 
assessed by using high resolution ultrasound to measure flow-mediated dilation (FMD) 
of the brachial artery in response to an increase in flow generated by a short period of 
reactive hyperaemia in the distal forearm. Impaired FMD in CKD77-80 is thought to be 
due in part to reduced clearance of endogenous inhibitors of eNOS: asymmetric 
dimethylarginines (ADMA) and its structural isomer symmetric dimethylarginine 
(SDMA)81 which compete with the substrate L-argine from which NO is synthesised by 
eNOS. Increased plasma concentations of ADMA and SDMA have been shown to be 
associated with increased risk of CV disease in adult patients with CKD.82,83 Other 
proposed mechanisms causing endothelial dysfunction include chronic inflammation, 
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raised homocysteine and dyslipidemia.84-86 Lack of normal endothelial repair has also 
been implicated as a possible cause for endothelial dysfunction although there is no 
paediatric data regarding this.87  
 
1.6.2. Structural changes in the artery: 
This may be due to atherosclerosis or arteriosclerosis. Atherosclerosis is thought to be 
initiated as a “response to injury” with the expression of adhesion molecules on the 
surface of the endothelium, migration of monocytes into the intima of the artery and 
interaction with lipoproteins to generate lipid rich plaques which may eventually obstruct 
the lumen.88 Arteriosclerosis refers to a calcification of the medial layer of larger elastic 
arteries.89 However, it is now clear that atherosclerosis and arteriosclerosis often co-
exist and that atherosclerotic lesions show varying degrees of calcification.90 
Calcification may, however, represent a distinct process with degeneration of elastin 
and inflammation leading to switch of vascular smooth muscle cells to an “osteogenic” 
phenotype whereby smooth muscle cells express an array of genes that are usually 
involved in bone formation.91,92 
Calcification (both medial and of atherosclerotic lesions) is thought to be a major cause 
of arterial stiffening of large arteries, particular the aorta. This imposes a number of 
adverse haemodynamic effects such as increased systolic pressure and decreased 
coronary perfusion.  
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Atherosclerotic lesions seen in older adults with CKD, are often calcified, have a patchy 
distribution and often described as having increased medial thickness, whilst diffuse, 
non-occlussive medial calcification is often seen in the younger adults with ERF.85  
In addition to metabolic, mechanical, infectious and inflammatory injuries93,94, disorders 
of calcium-phosphate metabolism may be key to the development of vascular 
calcification in CKD.31 These disorders of calcium-phosphate (Ca-P) metabolism include 
hyperphosphatemia, elevated calcium-phosphate product, increased calcium and active 
vitamin D intake and hyperparathyroidism. Hyperphosphatemia, increased active 
vitamin D and elevated levels of PTH fragments have all been shown to induce vascular 
smooth muscle cells transformation to osteoblasts.31,91,92,94,95  
 
1.6.3. Cardiac abnormalities in CKD: 
Hypertrophy of the cardiac muscle is a physiological adaptation in response to an 
increased load imposed over some time on the myocardium.96 Although this 
hypertrophied myocardium may be partially compensatory, it eventually may lead to 
heart failure.  
Cardiac remodeling of the left ventricle (LV) causing LV hypertrophy (LVH) is seen in 
two predominant patterns, concentric remodeling and hypertrophy and eccentric 
hypertrophy. Concentric patterns of altered LV geometry are classically associated with 
systemic arterial hypertension and arteriosclerosis, and eccentric hypertrophy as a 
result of volume loading conditions anaemia, fluid overload and arterio-venous fistulae 
all of which are seen in CKD.18 The pathophysiology of this was first described by 
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Grossman et al.97 According to their hypothesis, pressure overload of the LV leads to 
increase in peak systolic wall stress and parallel replication of sarcomeres, wall 
thickening, and concentric hypertrophy. The LV wall thickening continues until the peak 
systolic stress returns to normal, a feedback inhibition loop. Increasing pressure 
overload of the LV will therefore lead to progression of concentric hypertrophy. In 
contrast, upon LV volume overload, increased end diastolic wall stress leads to 
replication of sarcomeres in series, fiber elongation, chamber enlargement and 
eccentric hypertrophy. This chamber enlargement also causes increase in LV peak 
systolic stress and leads to wall thickening, until peak systolic stress is normalized. This 
symmetric increase in wall thickness to maintain the ratio of wall thickness and LV 
transverse radius normal, causes eccentric hypertrophy.97  
Increased LV mass and LVH seen in CKD are a consequence of the elevated systolic 
BP and pulse pressure, increased peripheral resistance and arterial stiffness. Over time 
maladaptive LVH develops leading initially to diastolic and then systolic dysfunction, 
compromised perfusion of the myocardium (coronary and subendocardial) causing 
ischaemia with decreased capillary density98, fibrosis99 and increased tendency to 
arrhythmia.35 Several other processes are thought to be involved in the cardiac 







1.7. Spectrum of CV abnormalities in children with CKD  
There are currently no data from any intervention study in children that describe the 
impact of modifying one or more risk factors on cardiovascular outcomes in children 
with CKD. All evidence is therefore based on observational cross-sectional patient 
cohorts.  
 
1.7.1. Endothelial dysfunction: 
This has been evaluated mainly using FMD. Unlike results in adult patients with CKD 
where impaired FMD predicts CV morbidity and mortality79,80, in children impaired FMD 
has been described in dialysis dependent patients102 but this has not been observed 
consistently in predialysis paediatric patients.103-105  
 
1.7.2. Large artery structural and functional changes: 
Large vessel intimal disease can be detected by measuring carotid intimal media 
thickness (cIMT) and there are now several small cross-sectional studies in children 
investigating this74,106, confirming in the majority, the onset of arterial disease from early 
CKD stages (Table 5).105,107-117 Some investigators have also described femoral artery 
intimal media thickness. Previous studies have been performed in children with early 
stages of CKD, those on dialysis and following renal transplantation and observed 
worse cIMT in patients on dialysis. Following transplantation abnormal cIMT has been 
shown to stabilize or regress.111  
46 
 
In addition to structural changes in large arteries, measures of arterial stiffening such as 
pulse wave velocity (PWV), a measure of arterial stiffness measured along elastic 
arteries, is widely used in adults and shown to be a good predictor of cardiovascular 
events and mortality in the general as well as dialysis population.118-120 PWV has been 
evaluated in only small childhood cohorts limited in those with ESKD.109,110 Other 
measure of arterial stiffening such as arterial compliance have also been evaluated in 
small populations of predialysis and dialysis dependent children.108  
 
Table 5: Large artery structural and functional changes reported in children with 






Litwin et al, 
2005
107 
n=55 CKD stage2-4; 37 on dialysis 
and 34 post-Tx; 270 controls 
Parameters : cIMT; femoral IMT; 
WCSA and lumen CSA of carotid 
 
All parameters increased in all 











n=44 CKD stage2-4; 16 on dialysis 
and 35 controls 
Parameters : cIMT; distensibility and 
stiffness of carotid artery 
 




product; and dialysis 
 
Covic et al, 
2006
109 
n=14 on dialysis and 15 controls 
Parameters : PWV and aortic AIx 
BP, age, height, weight, Ca and 
P levels accounted for 57% of 
the variability in AIx. Dialysis no 
impact on AIx or PWV 









Shroff et al, 
2007
110 
n=85 on dialysis and controls 
Parameters : cIMT and PWV. Also 
assessed cardiac calcification 
Increased cIMT had stiffer 
vessels and a greater 
prevalence of cardiac 
calcification 
 
iPTH level; dosage of 







26 children with CKD 2-4, ERF and 
Tx; 24 controls 
Parameters : cIMT z-score; brachial 
artery diameter and FMD. Also 
LVMI  
60% impairment of FMD; 
increased cIMT and reduced 




function, which may 










24 CKD stages 2-3; 32 ERF (19 had 
transplantation between two 
observations) 
Parameters : cIMT; WCSA and 
lumen CSA of carotid at baseline 
and 12 months later 
Patients post-Tx showed no 
further worsening and some 





duration ; degree of 
arterial damage 
prevalent at the time 
of grafting are the 
main determinants of 
persistent 







32 children with CKD 2-4, 28 ERF 
and 43 controls 
Parameters : cIMT. Also bone 
mineral density 
60% abnormal cIMT (both CKD 
and dialysis) 
 
lower fetuin-A and 
alkaline phosphatase 
levels and higher 
lumbar spine BMD 
with higher cIMT  
Civilibal et al, 
2009
113 
38 children on dialysis; 17 controls 
Parameters : cIMT. Also LV function 
 Worse cIMT with 
increased BP; 
Worse LV function 












60 children on dialysis 
Parameters : cIMT 
48% abnormal cIMT Hypercalcemia and 
total time on RRT 




n=101 eGFR: 43 and 97 healthy 
controls 
Parameter: cIMT  
median cIMT was 0.43 mm 




associated with 0.05 
mm (95% CI, 0.01–











10 children with CKD 3-5, 20 HD, 22 
transplant and 36 controls 
Parameter: cIMT 
Average cIMT in mm CKD: 
0.304 (0.238 to 0.389); HD: 
0.418 (0.374–0.477); 
Transplant:  0.411 (0.354 to 
0.466) 
 
Disease duration, BP, 
urea, lipid, and 
oxidative status 
parameters 
accounted for more 








n=134; 39 children with CKD 3-5, 53 
PD, 42 HD 
Parameter: cIMT and Einc  
 
 
Average cIMT in mm 
0.528±0.089 (all) 0.474±0.072 
(CKD) 0.533±0.079 (PD) 
0.571±0.092 (HD) 
dialysis (HD>PD), Ca 
x P product predicted 
cIMT 





reduced GSH but not 
inflammatory/oxidativ




1.7.3. Vascular calcification: 
Following the first description of coronary artery calcification (CAC) in a retrospective 
autopsy series by Milliner et al in 1990121, CAC has been evaluated in dialysis 
dependent children or young adults with childhood onset ERF, in several studies over 
the past 10 years.74 The prevalence rate of CAC observed in these studies varies 
between 10-20%34,110,123-127 in paediatric patients and prevalence rates between 47-92% 
for CAC in adults with childhood onset ERF.74,127 In the only longitudinal study 
assessing CAC in dialysis dependent children by Civilibal et al127, 7 of 48 dialysis 
dependent children with CAC were observed to have an increase, and 1 patient with 
CAC at baseline had decrease, after 2-year repeat assessment using spiral computed 
tomography. No new patients developed new lesions of CAC after 2-years on dialysis.  
Ca-P product was identified as a risk factor for CAC.  
 
1.7.4. Cardiac disease: 
Increased LV mass and LVH are the most commonly reported cardiac abnormality in 
both adult and paediatric patients with CKD (Table 6).18,40,41,43,44,54,64,65,74,128-134 In 
children with CKD we have observed elevated systolic BP but not diastolic, mean BP or 






Table 6: Studies in children with predialysis CKD reporting on increased LV mass and 
LVH 
LVH 
Number of patients 





geometry of LVH 
Significant risk factors 
identified 
Johnstone et al, 
1996
128 
n=32; eGFR:NR 22%; concentric hypertrophy - 
Mitsnefes et al, 2003
129
 n=25; eGFR: 39 24%; Geometry NR Reduced exercise capacity 
Poyrazoglu et al, 
2004
64 
n=10; eGFR: 17-48 50%; Geometry NR Anaemia 
Malikenas et al, 2005
130 n=56;  eGFR: 34 36%; 23% concentric & 13% 
eccentric 
Lower eGFR 
Matteucci et al, 2006
54 n=156; eGFR: 49 33%; 12% concentric & 21% 
eccentric 
ESCAPE study cohort 
Male gender anaeamia, 
increased PTH and BMI 
Mitsnefes et al, 2006
131 n=31; eGFR: 49 at 
baseline & 43 2-years 
later 
19% at baseline and 39% 
after 2-years 
High LVMI at baseline, 
anaemia, increase in iPTH and 
increased SBP load at night 
Weaver et al, 2008
132 n=45; eGFR: 46 17%; Geometry NR Increased cardiac output 
Rinat et al, 2009
65 n=57; eGFR: 15-60 16%; Geometry NR Systolic BP 
Mitsnefes et al, 2010
43 n=198; eGFR: 43 17%; 6% concentric & 11% 
eccentric 
CKiD study cohort 
Confirmed and masked 
hypertension on ambulatory 
BP monitoring 
Sinha et al, 2010
40 n=49; eGFR: 26 49%; all with eccentric 
hypertrophy 
EVELINA study cohort-1 
Systolic BP (clinic>ambulatory) 
and Ca-load in g/day for 





Number of patients 





geometry of LVH 
Significant risk factors 
identified 
Matteucci et al, 2013
41 n=84; eGFR: 49 LVH prevalence decreased 
from 38% to 25% 
ESCAPE Follow up study 
cohort 
improvement in myocardial 
function was associated with 
reduction in BP, independently 
of LVMI reduction 
Mencarelli et al, 2014
133 n=34; eGFR: 52 38%; concentric 84% No correlation of LVH with BP 
but with diastolic dysfunction 
Kupferman et al, 2014
44 n=436 followed up at 1, 
3 and 5 years 
eGFR: 44 
16% at baseline CKiD Follow up study cohort 
systolic BP, female 
sex, anemia, and use of non-
RAAS class of 
antihypertensive medications 
Sinha et al, 2015
134 n=83; eGFR: 33 36%; all with eccentric 
hypertrophy 
EVELINA study cohort-2 
elemental calcium 
content (g/kg/day) estimated 
from prescribed calcium-based 
phosphate binder dose and 
BMI z-score 
 
Diastolic dysfunction, a sign of impaired LV relaxation, is one of the earliest functional 
abnormalities of the left ventricle. This has been evaluated in children with CKD128,135 
and more recently using tissue Doppler imaging.136-144 These studies suggest worsening 
diastolic dysfunction with increasing loss of kidney function with reduced e′ velocities, 
increased E/e’ ratios with or without associated finding of LVH and increased 
myocardial performance index.135-138,141,143-145 Overt systolic dysfunction is unusually 
seen in children with CKD, particularly those with predialysis stages of CKD. Subclinical 
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systolic dysfunction though has been demonstrated in the predialysis population using 
‘midwall shortening fraction’ impairment instead of the ‘endocardial shortening fraction’ 
assessment.145,146 More recently, cardiac magnetic resonance147,148 or other advanced 
cardiac echocardiography techniques149,150 have been used to demonstrate early 
cardiac changes in children with CKD even before development of LVH or LV 
dysfunction.  
 
1.8. Risk factor: focus on blood pressure  
Despite a strong association between left ventricular mass, IMT and arterial stiffness 
with blood pressure in adults with CKD, the role of blood pressure in determining target 
organ damage in children with CKD remains controversial. In childhood CKD too, both 
LVH and arterial stiffness are thought to be determined less by blood pressure and 
more by other mechanisms primarily via disturbances in CKD-associated mineral bone 
disorders.  
Studies of pulsatile arterial haemodynamics have shown that although mean arterial 
pressure (MAP) and diastolic blood pressure (DBP) remains nearly constant along the 
arterial tree, systolic blood pressure (SBP) varies at different points along the arterial 
tree.151 Due to the phenomenon of pressure wave reflection and amplification peripheral 
SBP (pSBP) measured at the brachial artery usually exceeds central aortic SBP (cSBP) 
at the aortic root.152 In adults, cSBP is thought to relate more closely to target organ 
damage than peripheral SBP (pSBP).153,154 Differences between cSBP and pSBP are 
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more marked in younger compared to older adults155 and thus may be particularly 
important in children.  
The relative importance of cSBP in children has not been evaluated previously. 
Previous studies in children studying carotid and aortic structural and functional 
parameters have included cohorts of non-dialysis CKD, dialysis dependent and those 
following kidney transplantation. Importantly, they have reported limited carotid 
parameters without measuring cSBP. Litwin et al, reported carotid geometry, IMT and 
diameter but did not determine carotid stiffness and cSBP.107,111 Similarly, Mitsnefes et 
al, reported carotid IMT, geometry and carotid stiffness but did not use central blood 
pressure.108 In dialysis dependent children, Shroff et al, measured  carotid IMT and 
PWV110; whilst Covic et al, measured carotid IMT, PWV and carotid AIx109 but both did 





Childhood CKD is a devastating illness requiring life-long medical input, often 
progressing to ESKD, requiring dialysis and renal transplantation. Despite an increasing 
number of children now surviving through childhood and early adulthood, cardiovascular 
disease remains one of the major causes of death in individuals with childhood-onset 
CKD as young adults and it is likely this relates to onset of pre-clinical cardiovascular 
disease developing during childhood.  
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There are several modifiable CV risk factors in CKD, of which key risk factors relate to 
elevated BP and markers of abnormal Ca-P metabolism. Unlike in pre-dialysis CKD, in 
children on dialysis, abnormal mineral metabolism (high phosphorus, calcium-
phosphorus product, PTH and vitamin D metabolism) is thought to be one of the major 
determinants of cIMT and pulse wave velocity; whilst in children with predialysis CKD, 
elevated BP is highly prevalent. Commonly reported measures of end organ damage 
include measures of arterial stiffness and left ventricular hypertrophy, which in adults 
with CKD relate strongly to BP. Improved management of hypertension is a key aspect 
of management of adult CKD patients with recommendations for more stringent blood 
pressure targets in adults particularly those with proteinuric CKD.156 There are no 
current guidelines regarding optimal level of blood pressure control for cardiovascular 
outcomes in children with CKD.157 Available recommendations for BP levels in this 
cohort are extrapolated from the ESCAPE study – a randomised controlled trial to 
reduce the progression of CKD.158 
 
1.10. Purpose of this thesis 
 
Arterial stiffening relates to the severity of CKD, being greatest in those with dialysis 
dependent CKD, and is thought to be driven, at least in part, by excess body weight, 
hypertension and metabolic changes associated with CKD but their contribution to 
arterial disease progression remains poorly understood. The relationship of blood 
pressure with arterial disease remains unclear in the paediatric literature.  
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Previous studies performed in children pre-dialysis, those on dialysis and following 
kidney transplantation have measured PWV of the carotid-femoral pathway (i.e. mainly 
the aorta) and/or measures of carotid mechanics have been examined but these studies 
have been limited by lack of concurrent measures of carotid blood pressure (required to 
determine functional elasticity of the carotid artery). Furthermore, whilst the potential 
impact of age and blood pressure have been adjusted for, when comparing differences 
between children with and without CKD, this comparison has not been performed 
between age and blood pressure matched groups. 
The objectives of my thesis are to 1) to examine the use of an easy to perform, well 
tolerated technique to measure PWV in children. 2) to develop and validate a technique 
for estimation for central aortic systolic pressure in children. 3) to determine typical 
estimates of systolic blood pressure amplification and 4) to determine the association of 
arterial function and structure with severity of childhood CKD and to examine the 
relation of these measures to blood pressure. 5) to design a controlled trial to evaluate 































2.1.  Blood Pressure 
Blood pressure changes continuously throughout the cardiac cycle due to the 
interaction of the pressure generated by the ventricle with the impedance of the arterial 
tree. Systolic blood pressure (SBP) is the highest or peak pressure and occurs early 
after the start of contraction of the left ventricle and the lowest pressure, diastolic blood 
pressure (DBP) relates to the period of relaxation of the left ventricle. As a result of 
practical reasons relating to measurement, blood pressure has conventionally been 
assessed at the brachial artery through measurement of SBP and DBP. Mean arterial 
pressure (MAP) represents the average over time of blood pressure during the cardiac 
cycle and is often estimated from the empirical formula:  
MAP = DBP + (SBP-DBP) 
          3 
 
However, the relationship between MAP, SBP and DBP depends on the “form factor” or 
shape of the pressure waveform. 
 
2.2. Peripheral blood pressure measurement 
Peripheral systolic (pSBP) and diastolic blood pressure (pDBP) were measured 3 times 
in succession at the brachial artery by a trained observer after children had been seated 
for at least 5 minutes using a calibrated aneroid sphygmomanometer with an 
appropriate sized arm cuff according to British Hypertension Society (BHS) guidelines. 
The aneroid sphygmomanometer instruments were checked for accuracy annually.  
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Hypertension was defined as systolic and/or diastolic BP above the 95th percentile for 
age and height or if the patient was on anti-hypertensive therapy, using the Fourth 
Report Criteria (National High Blood Pressure Education Program Working Group).159  
 
2.3. Central blood pressure 
It is now well recognized that discounting hydrostatic pressure differences, MAP and 
DBP within conduit arteries are fairly constant throughout the arterial tree (being lower 
peripherally by only 1-3 mmHg than centrally at the heart).151,160 By contrast, SBP varies 
at different points in the arterial tree, with pSBP in the upper limb higher than central or 
aortic SBP (cSBP) measured at the aortic root. This phenomenon of peripheral pressure 
wave amplification is thought to be due to pressure wave reflections at the periphery of 
the arterial tree [Figure 2].161-163  
 
Figure 2: Schematic representation of the central pressure waveform, the peripheral 
pressure waveform and systolic pressure amplification as the pressure difference 
between the peripheral and central pressure values 
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Invasive catheter studies in adults have shown that the shape of the pressure wave in 
the ascending aorta is similar to the one recorded in the common carotid artery.  Direct 
application of tonometry on the carotid artery, a superficial and easily accessible pulse 
point, has been widely used in adults to record central blood pressure.  
 
2.3.1. Applanantion tonometry-derived estimate of cSBP (cSBPCarotid) at the 
carotid artery  
Direct application of tonometry at the carotid artery can be used to estimate non-
invasively cSBP at the carotid artery (cSBPCarotid) using the SphygmoCor system. This 
system uses a sensitive pressure transducer that lightly compresses the artery against 
underlying tissues (e.g. bone) [Figure 3].  
 
       




Following identification of the point of maximal arterial pulsation, pressing down lightly, 
the arterial wall is flattened against the underlying structure and the arterial pressure 
wave recorded. Carotid pressure waveforms are obtained from the right common 
carotid artery by applanation tonometry using a high-fidelity micromanometer (SPC-301; 
Millar Instruments, Houston, TX) and processed by the SphygmoCor device (Atcor 
Medical, Australia). This technique is possible to use in children but requires a 
significantly more experienced operator and a more co-operative older child. Overall, 















Figure 4: a. Carotid tonometry in an older child using the SphygmoCor device; and b. 





2.3.2. Applanantion tonometry-derived estimate of cSBP (cSBPRT) at the radial 
artery 
Central blood pressure can also be estimated non-invasively in adults “indirectly” using 
tonometry at the radial artery. This technique is also much easier to perform in children 
although still requires an experienced operator and co-operative patient young subject. 
Central blood pressure estimated using tonometric techniques has not been validated in 
children.   
 
 
Figure 5: Radial tonometry in a 6-year old using the SphygmoCor system 
  
Using this method radial waveforms meeting the inbuilt quality control criteria of the 
SphygmoCor device were ensemble averaged and converted to a corresponding aortic 
waveform using the inbuilt SphygmoCor generalised radial-to-aortic transfer function 






Figure 6: Acquisition of radial pressure waveforms obtained by the SphygmoCor 
system with radial to aortic transformation performed using the standard transfer 
function used in adults in a. 23 year old healthy woman; and b. 9 year old healthy girl 
 
Radial waveforms were calibrated from peripheral brachial measures of pSBP and 
pDBP, from which peripheral MAP was calculated by integrating the radial waveform. 
Transformed radial waveforms (i.e. estimated aortic waveforms) were calibrated from 
these values of peripheral MAP and pDBP to give a radial tononometric estimate of 





Estimates of cSBP in children using tonometric techniques have not been validated in 
children previously.  
2.4. Central pressure waveform and augmentation index 
 
2.4.1. Central pressure waveform  
The aortic (central) pressure pulse is thought to be a result of the summation of forward 
and backward pressure waves. The forward pressure wave (FPW) is generated by the 
ejection of blood from the left ventricle. It then travels along the arterial tree until it is 
reflected at sites of impedance mismatch in the distal circulation. The reflected wave 
travels backward (backward pressure wave, BPW) to add up with the FPW. Thus, the 
central pulse pressure (cPP) could be reduced into two pressure component 
waveforms. The pressure to the first systolic shoulder which is assumed to be the 
consequence of the FPW, and the pressure from the systolic shoulder to the systolic 
peak, also called augmentation pressure (AP) which is thought to be due to the BPW 




Figure 7: Schematic representation of augmentation pressure 
 
In Figure 8, a schematic representation of the central pressure waveform, is shown with 
the components used for pulse wave analysis.  
 
 
Figure 8: Schematic representation of the central pressure waveform and parameters 




Using the SphygmoCor system, following tonometry at the radial artery and use of 
generalised transfer function, the transformed central pressure waveform in a healthy 5-
year old child is shown (Figure 9). 
 
 
Figure 9: Synthesised aortic pressure waveform and components following pulse wave 
analysis. The radial pressure waveform was acquired using applanation tonometry with 
the SphygmoCor device in a healthy 5-year old.    
 
2.4.2. Aortic augmentation index (AIx) 
Augmentation index is defines as the ratio of augmenting pressure over pulse pressure, 
expressed as a percentage. Central pressure waveform analysis is used to calculate the 








Aortic augmentation index (AIx) = 100 x  AP 
                                                    cPP 
 
where, AP is the augmented pressure, cPP is the central pulse pressure.  
AIx provides an indication of the consequence of reflected waves on the aortic pressure 
waveform and it reflects the contribution of the reflected wave on systolic pressure and 
pulse pressure.  
In young healthy adolescent subjects, aortic augmentation index is usually negative or 
near zero but has been found to be higher in children younger than 10 years old and 











Figure 10: Acquisition of radial pressure waveform using applanation tonometry and 
computation of aortic Augmentation Index in a.13 year old healthy boy and b. 5 year old 
healthy boy 
2.5. Large artery biomechanical properties: structural and functional 
 
2.5.1. Pulse wave velocity 
Pulse wave velocity (PWV) is the velocity of the blood pressure wave as it travels along 
the arterial tree and is determined by the elasticity, diameter and thickness of the 
arteries. For an artery that approximates an idealized thin walled elastic tube, PWV is 






Where E is Young’s elastic modulus. PWV is thus proportional to the square root of the 
incremental elastic modulus (Einc). The measurement of PWV is regarded as one of the 
most robust methods to measure arterial stiffness. It is usually determined by measuring 
the transit time (T) of the pulse between a proximal and distal site:  
PWV= Distance between the two sites 
 
Although, PWV has been measured over different arterial segments including, brachial-
ankle, brachial-femoral, the “aortic” PWV measured over the carotid-femoral pathway 
(PWVcf or PWVa) is considered to be the most informative measurement in adults. In 
children, only PWVcf has been described (Figure 11). PWVcf has been shown to be 
repeatable, reproducible and to be a significant predictor of mortality in adults with and 
without renal disease, including elderly, diabetic and hypertensive adults.120,166 It is 











Figure 11: Schematic representation of examples of published pulse wave velocity 
measurement sites in adults and children 
 
PWVcf is usually measured in adults by sequential recording at the carotid and femoral 
artery using electrocardiogram-referenced (ECG-referenced) applanation tonometry 
such as the SphygmoCor system (AtCor Medical, Australia).  
The transit time, can be calculated by the time delay between the carotid and femoral 

















Figure 12: Schematic representation of the time difference (‘delay’) in pressure waves 
between a proximal and distal arterial pulse point when measured simultaneously. 
 
2.5.1.1. PWV measured using the SphygmoCor system 
In the Sphygmocor system, the R wave of the QRS complex of the ECG is the 
reference point and the transit time is calculated as the difference between ‘t1’, the 
delay of the proximal pressure wave (e.g. carotid) and ‘t2’, the delay of the distal 
pressure wave (e.g. femoral) with the R wave of the QRS complex of the ECG, both 








Figure 13: Schematic representation of the calculation of PWVcf, where t denotes t2 - 
t1, the time difference (‘delay’) in pressure waves between a proximal and distal arterial 
pulse point and ‘d’ the distance between the two pulse points. PWV is the ratio of t/d in 
m/s 
 
Applanation tonometry using the Sphygmocor system remains most widely reported and 







PWVcf  (m/s) = d / t 







Figure 14: a. Using the SphygmoCor system to perform PWVcf in a older child; and b. 
Example of the output of the Sphygmocor system in a 14 year old healthy child with 
carotid artery pressure and femoral artery pressure waveforms shown in the upper and 
lower panels respectively (in white) together with the reference ECG (in yellow) 
 
The SphygmoCor system though is expensive; with additional significant limitations to 
its use in children as it requires a trained operator, the carotid artery is difficult to 
applanate as the supporting tissues are elastic and access to the femoral artery in the 
inguinal area may be distressing, particularly in adolescents.  
There are a number of instruments that allow PWVcf to be measured in adults using 
different techniques (applanation tonometry, ultrasound, pulse volume recording, 
plethysmography and Magnetic Resonance Imaging), using different algorithms – 
measuring PWV sequentially or simultaneously at two different pulse points. 
Measurements of PWV using differences technologies have limited agreement and this 




2.5.1.2. PWV measured using the Vicorder system 
The Vicorder system (Skidmore Medical, UK) is a relatively recently introduced system 
that uses simultaneous volumetric pressure recordings from a sensor placed over the 
carotid artery and a thigh cuff placed over the femoral artery (which can be placed over 
light clothing, Figure 15). It is thought to be less operator dependent than a tonometric 









Figure 15: a. & b. Using the Vicorder system to perform simultaneous PWVcf in an 
older child; and c. & d. Example of output of the Vicorder system in a 12 year old 
healthy child with simultaneous recordings of the c. carotid and d. femoral  pressure 
waveforms  
 
The Vicorder system can also be used to measure brachial-femoral PWV (PWVbf), 
whereby the proximal sensor is a cuff is placed over the brachial artery. This may be 
more acceptable to young children than the neck cuff.  
 
2.5.1.3. Measurement of distance 
Path lengths are usually estimated from the distance between surface markings. For the 
SphygmoCor PWVcf path length was measured with a tape measure from the 
suprasternal notch to the femoral pulse at the point of applanation. For the Vicorder 
system, PWVcf was taken as the distance from the suprasternal notch to the top of the 
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thigh cuff. That for PWVbf path as the distance from the top of the arm cuff to the top of 
the thigh cuff.  
 
2.5.1.4. Number and quality control of measurements of PWV  
Data was considered acceptable from the Vicorder system when there were at least five 
sequential good quality waveforms were obtained from each cuff. For the Sphygmocor 
system, measurements were rejected if the standard deviation of the mean transit time 
exceeded 6% (automatically flagged by SphygmoCor). Three measurements were 




2.5.2. Carotid dimensions 
 
2.5.2.1. Carotid intima medial thickness (cIMT) and diameter 
The Mannheim Consensus provides recommendations for the measurement of IMT in 
adults only168 although the underlying principles are the same for children. There are 
now some published normative data for carotid IMT (cIMT) in children and suggest 
significant positive correlation of body dimensions and SBP with cIMT with gender 
differences in particular between adolescents.169,170  
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B-mode ultrasound is the most common method used to evaluate intima medial 
thickness (IMT). There are two main methods of measuring IMT using this technique. 
Most frequently used method involves the manual cursor placement technique, with IMT 
measurement at several points (usually three to six) on each side, and then averaging. 
The second technique is also based on manual cursor placement, but the investigator 
draws a line on the upper border of the intima and a second line on the lower border of 












Figure 16: a. Acquisition of normal ultrasound scan of the carotid artery, with colour 
flow imaging; and b. an optimised image with walls seen more clearly and the upper 
border of intima and lower border of media on the posterior wall highlighted 
 
In this study, we imaged the right common carotid artery (CCA) using the ART.LAB 
system.171-173 A linear transducer (range 4 to 13MHz) was used to image a 4cm 
segment of artery approximately 1 to 5 cm proximal to the flow divider, with mean cIMT 
obtained from automated analysis of the posterior wall over this segment of the 
artery.174,175 This method is recognized as one of the most robust measures of IMT 
since the reproducibility of common carotid IMT measurements is higher than that of 
other segments.176  
After obtaining the desired longitudinal view of the CCA, the software highlights the 
diameter and IMT and, each radio frequency line is analyzed backward and forward in 
real time (Figure 17). Each interface is determined using a proprietary algorithm, taking 
advantage of the very high dynamic of the radiofrequency signal to define interfaces 





Figure 17: Acquisition of ‘Screen view’ for analyses of vessel diameter and IMT with the 
ART.LAB system 
 
The ART.LAB system software extracts the raw radiofrequency data from image to 
calculate cIMT with greater precision. Measurements of the last 6 cardiac cycles are 
displayed on the screen with the mean diameter and IMT calculated (Figure 18). Three 
average values of cIMT were derived (each obtained over 6 cardiac cycles) and the 













Figure 18: Acquisition of ‘Results view’ for vessel diameter and IMT with the ART.LAB 
system 
 
2.5.2.2. Carotid artery distension  
Radiofrequency wall-tracking was used to obtain distension waveforms averaged over 6 
cardiac cycles. Diastolic internal lumen diameter (Dd), systolic internal lumen diameter 
(Ds) and carotid distension (∆D = Ds - Dd) were derived from each distension waveforms 






Measurements for last six cardiac 
cycles displayed on the screen 






Figure 19: Acquisition of ‘Results view’ for artery distension and diameter with the 
ART.LAB system 
 
The following measurements/indices of carotid artery geometry and elasticity were then 
derived from these measures of lumen diameter, distension and IMT177 
2.5.2.3. Other carotid artery structural measurements  
a. Carotid wall thickness radius ratio (CWTR) 
   CWTR = 2 × IMT 
                 (Dd+IMT) 
b. Wall cross-sectional area (WCSA) 
WCSA = π [(Dd+IMT)
2 – Dd
2]  
           4 
 
 
Values of carotid diameter and 
distension shown on-screen 
Artery walls tracked with  




2.5.2.4. Carotid artery functional measurements  
a. Cross-sectional compliance coefficient (CC), the absolute change in lumen area 
during systole for a given pressure change.   
CC = ∆A 
          PP 
where, ∆A is the change in cross-sectional area (∆A = π∆Dd
2/4) and PP the local pulse 
pressure. 
b. Cross-sectional distensibility coefficient (DC), the relative change in lumen area 
during systole for a given pressure change. 
DC = (∆ A / A) 
          PP 
where, A is lumen area in diastole (A = πDd
2/4) 
c. Circumferential wall stress (CWS), calculated using the Lame equation178,179 
CWS = MAP x Dm  
           2 x IMTm 
where, Dm and IMTm are the mean values of internal diameter and wall thickness during 
the cardiac cycle.  
d. Young’s incremental Elastic Modulus (Einc), elasticity that is independent of the vessel 
geometry. 
Einc = [3(1 + A / WCSA)]  




2.6. Laboratory methods  
Renal function was determined by estimating glomerular filtration rate (GFR) using the 
Schwartz formula13 with correction factor of 31 in our population with CKD.40,180,181 
Stages of CKD were defined according to published definitions using KDOQI 
criteria.16,17  
All subjects including healthy volunteers (if agreed for blood tests) also had ‘routine’ 
biochemical investigations including haemoglobin, corrected calcium, phosphorus and 
intact parathyroid hormone (iPTH). All routine biochemical investigations were 
measured once and on the same day as the vascular assessments. 
All subjects were evaluated at the time of a planned clinical review and underwent as 
part of routine clinical care clinical and study appropriate review of clinical history and 
physical examination, anthropometry including height, weight and body mass index, 
medication review and blood tests. In all subjects, blood and urine specimens were 









Chapter 3 : Measurement of pulse 
wave velocity in children: 
comparison of volumetric and 
tonometric sensors, brachial-













Pulse wave velocity (PWV) is a measure of arterial stiffness which when measured 
along large elastic arteries such as the aorta is highly predictive of cardiovascular (CV) 
risk in adults166 particularly in patients with chronic kidney disease (CKD).120 Children 
with CKD including those with Established Renal Failure (ERF) requiring renal 
replacement therapy have an increased risk of mortality secondary to cardiovascular 
disease both during childhood and as young-adults.19,23,27 These young adults with 
childhood onset ERF exhibit mortality rates about 30 fold higher than age matched 
peers with no renal disease.19,23 It is now widely accepted that the risk factors for these 
adverse cardiovascular events develop during childhood and that they are likely to 
evolve with progressive renal dysfunction.182  
In these children with moderate to severe CKD, arterial stiffness may contribute to 
cardiovascular morbidity/mortality either through remodeling of the left ventricle pre-
disposing to sudden cardiac death73 or through other mechanisms. Therefore, 
measurement of arterial stiffness in children with CKD may be particularly important. 
Reference values for PWV in children have recently been published183, which may aid 
evaluation of PWV in paediatric clinical studies. 
PWV is usually measured between the carotid artery and the femoral artery by 
sequential ECG-referenced arterial applanation tonometry (using a pressure sensitive 
transducer to lightly compress the artery) or other arterial pressure or flow velocity 
sensors. The SphygmoCor system (AtCor Medical, Australia) uses ECG-referenced 
applanation tonometry and is one of the most widely used systems in adults for 
measurement of carotid-femoral PWV (PWVcf). There are some limitations of this 
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system for use in children: tonometry requires a trained operator and access to the 
femoral artery in the inguinal area may be distressing particularly in adolescents.  
The Vicorder PWV system (Skidmore Medical, UK) uses simultaneous volumetric 
pressure recordings from a sensor placed over the carotid artery and a thigh cuff placed 
over the femoral artery (which can be placed over light clothing) is less operator 
dependent than a tonometric system and does not require the patient to undress. The 
Vicorder system can also be used to measure brachial-femoral PWV (PWVbf), whereby 
the proximal sensor is a cuff is placed over the brachial artery. This may be more 
acceptable to young children than the neck cuff.  
The relation of Vicorder brachial-femoral measurements to carotid-femoral 
measurements is unknown. Nor is it clear whether there is a close correlation between 
carotid-femoral measurements obtained by Vicorder and SphygmoCor systems.  Good 
agreement between the devices has been reported in children and young adults184,185, 
in older adults and in pregnant women.186 However, others have questioned the 
suitability of the Vicorder device as an alternative to more established methods.187  
 
3.2. Objectives 
The purpose of this study was to compare PWVcf and PWVbf obtained using the 
Vicorder system and to compare values of PWVcf obtained by the Vicorder and 






3.3.1. Study population and protocol 
The study population included a convenience sample of 156 children who were 
recruited from paediatric renal and hypertension outpatient clinics at the Evelina London 
Children’s Hospital London, UK. No formal sample size estimate was performed. The 
local research ethics committee approved the study, and written informed consent was 
obtained from all parents or guardians. In older children, written assent was also 
obtained.   
Seated blood pressure was measured in triplicate using a calibrated aneroid 
measurement by a single trained observer. All 156 patients had measurements of both 
PWVcf and PWVbf by Vicorder. Measurements were performed supine using 
appropriately sized cuffs as recommended by the manufacturer. Path lengths were 
determined using a measuring tape. That for PWVcf was taken as the distance from the 
suprasternal notch to the top of the thigh cuff. That for PWVbf path as the distance from 
the top of the arm cuff to the top of the thigh cuff. Three measurements were performed 
in each mode if the patient remained comfortable. Data was considered acceptable 
when there were at least five sequential good quality waveforms were obtained from 
each cuff. 
Those patients who were able to tolerate the measurement also had measurements of 
PWVcf by SphygmoCor.  SphygmoCor PWVcf path length was measured from the 
suprasternal notch to the femoral pulse at the point of applanation. Measurements were 
rejected if the standard deviation of the mean transit time exceeded 6% (automatically 
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flagged by SphygmoCor). As with Vicorder, measurements were done in triplicate 
whenever possible. All measurements were made by two experienced trained 
observers. 
3.3.2. Statistics 
Data analysis was performed using SPSS 19.0 (SPSS, Chicago, Illinois). Pearson’s 
correlation was used to assess the correlation between measures obtained by the 
different methods. Agreement between methods was assessed using the Bland-Altman 
plots.188 Differences between correlation coefficients were tested by using the Fisher r-
to-z transformation. Within-subject standard deviation (SD) and coefficients of variation 
(SD as percentage of mean) were used to assess the repeatability of successive 
measures. Linear regression analysis was used to test the association of PWV with age 
and blood pressure. The regression equation between PWVcf and PWVbf Vicorder was 
used to adjust PWVbf (Vicorder) to obtain the best estimate of PWVcf (Vicorder), by 
multiplying PWVbf by 0.67, the reciprocal of the slope of the regression of PWVbf vs. 





3.4.1. Study population characteristics 
One hundred and fifty six children (42% female) aged 3-18 years were recruited. Of 
these, 110 (71%) had chronic kidney disease (CKD), 27 (17%) had hypertension and 19 
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(12%) were normal healthy subjects. There were no significant differences in clinical 
characteristics between the entire cohort and the subset able to tolerate carotid and 
femoral tonometry. Children with CKD were of similar age, height, BMI and BP level to 
controls (data not shown) and therefore data for entire cohort are shown together 
(Table 7).  
 








Parameter Range Mean±SD Range Mean±SD 
Age (years) 3.2 – 17.9 11.7±3.6 4.3-17.9 12.2±3.3 0.21 
Height (cm) 89.5 – 189.2 146.9±22.4 102.8-189.2 150.5±19.8 0.16 
Weight (kg) 12.8 – 116.1 48.0±22.9 16.6-111.8 50.3±22.0 0.41 
BMI 13.1 – 41.7 20.9±5.6 13.6-41.7 21.1±5.4 0.78 
Systolic blood pressure (mmHg) 71 – 147 107±16 71-147 108±17 0.64 
Diastolic blood pressure 
(mmHg) 








3.4.2. Comparison of PWV by Vicorder over carotid-femoral and brachial-femoral 
paths 
The mean difference between Vicorder PWVcf and PWVbf was 1.81±1.21m/s. Vicorder 
PWVbf measurements were significantly higher than Vicorder PWVcf measurements 
(P<0.001) but were closely correlated (R= 0.75, P <0.001, Figure 20a). Limits of 
agreement (LoA) between Vicorder PWVcf and PWVbf were 0.62 to -4.25m/s (Figure 
20b) with a significant systematic difference between the two measurements, with a 
greater difference between devices as PWV increased. The observation of an 
increasing difference between devices as PWV increased was the rationale to perform a 
correction for this systematic difference which was made assuming a linear relationship 
between PWVcf and PWVbf by Vicorder. We obtained the best prediction of PWVbf, the 
mean difference between PWVcf (Vicorder) and corrected PWVbf (Vicorder) was 0.00± 




Figure 20. Comparison between pulse wave velocity (PWV) measurements by the Vicorder over different paths carotid-
femoral (PWVcf) and brachio-femoral (PWVbf) a. Correlation between Vicorder PWVcf and PWVbf,  b.  Bland-Altman plot 









3.4.3.  Comparison of PWV by Vicorder and SphygmoCor 
Of the 156 patients, 122 (78.2%) were able to tolerate carotid and femoral tonometry, 
with at least one valid result acquired. In comparison to the overall cohort, those with 
failed tonometry were significantly younger (9.84±4.2 years vs 11.7±3.6, p=0.008), but 
with no difference between groups for BMI (p=0.53) and gender (p=0.66). Declining 
tonometry (n=6), failure to stay still (n=6), and failure to palpate one or more pulse 
and/or poor quality trace (n=5 each) were the commonest causes of failed tonometry.   
PWVcf by Vicorder was significantly lower than that measured by SphygmoCor 
(P<0.001) and only moderately correlated with SphygmoCor PWVcf (R=0.50, P <0.001, 
Figure 21a).  The mean difference between Vicorder PWVcf and SphygmoCor PWVcf 
was 0.31±0.88m/s.  The LoA between Vicorder PWVcf and SphygmoCor PWVcf were -
1.46 to 2.07m/s. (Figure 21b).  
 
Figure 21: Comparison between pulse wave velocity (PWV) measurements by the 
Vicorder and Sphygmocor over the carotid-femoral path a. Correlation between 
SphygmoCor PWVcf and Vicorder PWVcf,  b. Bland-Altman plot of agreement between 





The path lengths used for the two instruments were highly correlated (R=0.84, 
P<0.0001) and the correlation between Vicorder transit time and SphygmoCor transit 
time was similar to that between corresponding values of PWV (R=0.52 and R=0.50 for 
correlations between transit times and PWV respectively, both P < 0.001). Vicorder 
PWVbf was marginally less well correlated with SphygmoCor PWVcf (R = 0.451, P < 
0.001), with a mean difference of 1.48±4.54m/s. Using corrected values of PWVbf 
against SphygmoCor PWVcf, the mean difference was -0.34±1.11m/s (Figures 22a and 
22b) with LoA -2.56 to 1.88m/s. 
 
 
Figure 22: Comparison between pulse wave velocity (PWV) measurements by Vicorder 
over the brachio-femoral (PWVbf) and Sphygmocor over the carotid-femoral path 
(PWVcf) a. Correlation between SphygmoCor PWVcf and corrected Vicorder PWVbf,  






We observed no significant difference between boys and girls for the difference 
between corrected PWVbf (Vicorder) and SphygmoCor PWVcf (-0.43 vs. -0.22 m/s; 
P=0.49). Similarly, there was no significant difference by age subgroups (<10, 10–15, 
>15 years) for the difference between corrected PWVbf (Vicorder) and SphygmoCor 
PWVcf (Table 8) 
 
Table 8: Comparison of the differences between corrected PWVbf (Vicorder) and 



































Aged < 10 years 
Aged 10-15 years 



















* P value testing for the difference by gender and age subgroups for the difference between corrected 









3.4.4. Repeatability of Vicorder and SphygmoCor measurements 
Within subject coefficients of variation were calculated for subjects with at least two 
measurements for each device with repeated measurements performed by the same 
researcher measured consecutively at the same study visit. Duplicate or triplicate 
PWVbf measurements were obtained for all patients. Six patients only had one PWVcf 
(Vicorder) recorded, as some measurements were discarded due to poor quality traces 
or intolerance of the neck cuff. Of the 122 patients included in the SphygmoCor subset, 
101 had duplicate or triplicate measurements of acceptable quality. The time taken to 
perform 3 consecutive measurements was approximately 5 and 10 minutes for Vicorder 
and SphygmoCor respectively. Within subject variation for repeated measures were 
5.9%, 7.8%, and 8.5% for PWVbf (Vicorder), PWVcf (Vicorder) and PWVcf 
(SphygmoCor) respectively.  
 
3.4.5. Correlation of Vicorder and SphygmoCor measurements with age  
Linear regression was used to determine the correlation between PWV and age for 
each device. Pearson’s correlation coefficients were 0.50, 0.53 and 0.40 (each P< 
0.001), for SphygmoCor, Vicorder PWVcf and Vicorder PWVbf (Figure 23). There was 





Figure 23: Variation of mean and SD of PWV according to age, as calculated by each 
device over different paths.  
 
3.4.6. Discrimination of blood pressure with Vicorder and SphygmoCor 
To investigate the discriminatory ability of the various PWV measurements performed 
by the two instruments we performed a sub-analysis in an age and gender matched 
cohort of two groups of children (n=20) at the extremes of the blood pressure 
distribution (and thus assumed to have stiff and compliant arteries for the high and low 
blood pressures respectively) to detect stiff and compliant aortae. Receiver operating 






Figure 24: ROC curve showing area under the curve for each method of PWV 
measurement 
 
The area under the curves was 0.913 (95% CI, 0.82-1.00) for PWVcf (SphygmoCor), 
0.863 (95% CI, 0.73-1.00) for PWVcf (Vicorder) and 0.900 (95 CI, 0.78-1.00) for PWVbf 




Carotid-femoral measurements have until recently been used to estimate large artery 
PWV but such an approach can be difficult to use, especially in children. In the present 
study, carotid-femoral tonometry data could not be acquired in 22% of our children (34 
out of 156).  Usually this was due to practical problems in the younger children such as 
the need to sit still, difficulty in palpating pulses or obtaining traces of adequate quality. 
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In a few patients with arrhythmias, such as benign sinus tachycardia of childhood, the 
SphygmoCor was unable to compute the PWV accurately. Although we do not have any 
formal data regarding tolerance and comfort of subjects for either system, the Vicorder 
volumetric recoding system was used successfully (for both carotid-femoral and 
brachial-femoral measurements) in all children and measurements showed similar or 
better repeatability than those obtained using the SphygmoCor system. When 
comparing the repeatability and tolerability of Vicorder and SphygmoCor, it is important 
to note that our results could have been influenced by the order in which the 
instruments were used.  
 
When comparing the agreement between Vicorder PWVcf and SphygmoCor PWVcf, 
there was only moderate correlation and LoA were relatively broad. LoA for carotid-
femoral measurements for the two devices were -1.46 to 2.07m/s, slightly greater than 
the LoA of  -1.0 to 1.7m/s obtained by Kracht et al184 in a study on children and 
adolescents, the mean age (11.1 years) of which was similar to the children in our study 
(11.7 years). Our LoA were also slightly greater than those reported by Kis et al (-0.91 
to 2.1, using the manufacturer’s recommended calculation of path length) in a slightly 
older group (mean age 16.7 years).185 Our LoA were, however, better than those 
reported by van Leeuwen et al187 and thus sit within the range reported to date. 
Although the agreement between PWV obtained by the Vicorder and SphygmoCor 
methods has been described as “excellent”, it is worth noting that since the mean PWV 
with SphygmoCor was 5.62m/s, a LOA of 2m/s represents an error of 36%. Thus values 
of PWV obtained by the two methods can hardly be regarded as interchangeable. 
Differences between methods could arise as a result of a) inaccuracies in estimating the 
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true path lengths, b) differences in the true path lengths, the point of pulse recording for 
the Vicorder system being distal to that for the SphygmoCor, c) differences in estimation 
of the timing of the arterial pulse waveforms at the two sites. The close correlation 
between the estimates of path length used for the two systems and the fact that the 
correlation between transit times was similar to that between values of PWV suggests 
that differences arise in large part through differences in timing algorithms. It is also 
noteworthy that in other studies which have used a variety of correction factors to adjust 
for inaccuracies in estimation of length, the impact on the SD of the mean difference is 
negligible which would again point to a difference in timing algorithm as the main source 
of variation between the methods. The SphygmoCor system (as in this study) is usually 
used with a well established  intersecting tangent algorithm to identify the foot of the 
arterial pulse whereas the Vicorder uses a cross-correlation algorithm which may be 
influenced by differences in waveform morphology between the carotid and femoral 
sites.189  
  
To our knowledge, this is the first study to evaluate the measurement of brachial-
femoral PWV. This is an even simpler technique requiring very little user training, which 
is well tolerated by children. Good quality waveforms can be acquired from most 
brachial arteries, with no venous artefacts as are often seen with a neck cuff.  The 
brachial-femoral measurement measures the difference between pulse transit from the 
aorta to brachial artery and aorta to femoral rather than that between the aorta to carotid 
and aorta to femoral. The two measurements might, therefore, be expected to differ 
because of the longer and more muscular route from the aorta to the brachial artery 
compared to that to the carotid: the right innominate being common to both routes but 
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the former incorporating the subclavian and brachial arteries rather than just the 
common carotid. However, provided there is a close correlation between PWV in the 
carotid and subclavian/brachial arteries, PWV obtained over the two pathways might be 
expected to correlate well. This was indeed the case with a high correlation of R=0.75 
between PWVbf and PWVcf. When adjusted for differences in estimation of path length, 
PWVbf by Vicorder agreed almost as well with SphygmoCor PWVcf as did PWVcf by 
Vicorder. We observed a systematic bias with greater difference between the PWVbf 
and PWVcf measurements by Vicorder with increasing PWV. The corrected PWVbf is 
likely to be generalisable to other paediatric populations but this needs to be tested 
prospectively because although the adjustment is likely to be driven by PWV it is 
possible that other factors such as age and/or height influence the relationship between 
the two methods of measurement. As PWV is predominantly driven by BP, our analyses 
to discriminate extremes of PWV measurement using different instruments in children 
with high and low BP must be interpreted with caution. Furthermore, we acknowledge 
limitations imposed by a relatively narrow range of PWV and BP. The correlation 
coefficient has limited value for assessing the agreement between two methods of 
measurement of the same quantity since the correlation coefficient depends on the range of 
values over which the correlation is assessed, being higher for a greater range.188   
 
In conclusion, the Vicorder technique is easy to use, is well tolerated by children and 
gives excellent repeatability when measurements are made by the same observer 
consecutively.  Further data are needed to show inter and intra observer variability 
when measured over repeated visits. Values obtained over the brachial-femoral path 
are closely correlated with those from the carotid-femoral path. However, Vicorder 
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carotid-femoral values are only moderately correlated with those obtained from the 
SphygmoCor system with the difference likely to be due to differences in the timing 
algorithms used in the two systems. Although measurements are not interchangeable 
PWVbf appears as reproducible and as likely to discriminate between groups with 
differing arterial stiffness as other measures. Since it is the simplest measure to use we 
would recommend this is applied more widely in children and our findings tested in 



























Chapter 4 : Central aortic blood 
pressure from ultrasound wall-
tracking of the carotid artery in 
children: comparison with invasive 












Systolic blood pressure (SBP) is amplified along conduit arteries such that peripheral 
SBP (pSBP) measured at the brachial or radial artery usually exceeds central aortic 
systolic pressure (cSBP) at the aortic root.152 By contrast, mean arterial pressure (MAP) 
and diastolic blood pressure (DBP) are almost identical at central and peripheral 
sites.120 In adults, cSBP is thought to relate more closely to target organ damage than 
peripheral SBP (pSBP).153,154 Differences between cSBP and pSBP are more marked in 
younger compared to older adults155 and may be particularly important in children.190 
However, non-invasive estimates of cSBP have not been validated in children and there 
is limited information on the magnitude of SBP amplification in children.191,192 
 
4.2. Objectives 
The aim of the study was to i) compare estimates of central aortic systolic pressure 
obtained from radiofrequency ultrasound wall-tracking of the carotid artery171,172 with 
that measured directly using a pressure-tipped catheter placed in the aortic root at the 
time of arterial cannulation; ii) to compare the values of cSBP obtained from non-
invasive radiofrequency ultrasound wall-tracking of the carotid artery with those 
obtained using applanation tonometry at the radial artery and a radial-to-aortic transfer 
function152; iii) to determine typical SBP amplification in children with and without 







The study was performed at Evelina London Children’s Hospital (ELCH), UK with the 
approval of the local Research Ethics Committee. Written Informed consent was 
obtained from parents and/or children for participation in the study. 
 
4.3.1. Study 1: Invasive validation of carotid wall tracking-derived compared with 
measured aortic cSBP 
Children aged 2-18 years (n=9) attending for diagnostic and/or interventional 
arteriography for the investigation/treatment of suspected renovascular disease or 
congenital heart disease were recruited from the Paediatric Nephrology and Cardiology 
departments at ELCH. Children with arrhythmias or clinical evidence of heart failure 
were excluded from the study. 
 
4.3.1.1. Invasive measurement of central SBP (cSBPinv)  
Central blood pressure was measured in children undergoing planned diagnostic and/or 
interventional arteriography for the investigation and/or treatment of suspected 
renovascular disease or congenital heart disease. The procedure was performed under 
general anaesthetic and access to the femoral artery established. A 4-FR catheter 
passed through the femoral arterial sheath over a guidewire and a high fidelity pressure-





Figure 25: Catheter positioned at the proximal aortic root 
 
ComboWire®  XT 9500 series, pressure and flow wires (diameter 0.014”, ComboWire®, 
Volcano Corporation, San Diego, CA, USA) were used. In addition to a pressure sensor 
mounted on the tip of the wire, this wire additionally also has a Doppler probe which 
enables the recording of the velocity of the blood flow (Figure 26). The aortic pressure 
waveforms were recorded digitally at 1 kHz on a computer through an analog-to-digital 





Figure 26: a. Schematic of the ComboWire®  XT 9500 series, pressure and flow wire 
and b. The ComboMap monitor 
Flow velocity and pressure waveforms were aligned according to the specifications 
provided by the manufacturer’s engineers but for the purposes of my thesis only 










4.3.1.2. Invasive validation of carotid wall tracking-derived aortic cSBP  
Carotid distension waveforms were obtained by radiofrequency ultrasound wall tracking 




Figure 27: The ART.LAB system in use on a 6-year old child 
 
The ART.LAB system provides very high resolution images, with a pixel size of 23μm x 
23μm, and a very high frame rate of 600Hz and data is recorded in 14 lines 
perpendicular to the probe. The wall tracking system thus provides continuous beat to 
beat movement of the artery and allows measurement of the distention of the artery, its 






Figure 28: Acquisition of distension waveforms obtained by radiofrequency ultrasound 
wall-tracking of the carotid artery using the ART.LAB system 
 
At the time of acquisition of the digital recording of the invasive aortic pressure 
waveform, carotid distension waveforms were obtained simultaneously over a 5 to 10 
second period. Up to 5 repeat recordings of such 5-10 second periods of simultaneous 
carotid and aortic waveform recordings were obtained. Carotid distension and aortic 
waveforms were post-processed using custom in-house software developed in MATLAB 
(MathWorks, Cambridge, UK). Waveforms from each 5-10 second period of recording 
were ensemble averaged. Invasive values of cSBP, MAP and DBP (cSBPinv, MAPinv 
and DBPinv) were obtained from the ensemble averaged aortic waveforms.  
 
Distension waveforms were initially calibrated with mean and maximum distension 
values (Figure 29) and cSBP estimated (cSBPcarotid) from the ensemble averaged 




previously by Kips el al (Figure 30).153 Processing was performed automatically but an 
experienced observer first inspected all waveforms to exclude artefacts.  
 
 
Figure 29: Calibration of the distension waveform with mean and maximum distension 
values 
 
cSBPcarotid = DBPinv  +   MAPinv – DBPinv   x  Dmax 
Dmean 
Figure 30: cSBPcarotid estimated by the calibrated distention waveforms and the invasive 
values of the aortic pressure 
 
4.3.2. Non-invasive comparison between radial tonometry-derived versus carotid 
wall tracking-derived estimates of cSBP 
 
Children aged 2-18 years (n=84) were recruited from the hypertension and nephrology 
out-patient clinics of the ELCH and healthy control children were recruited from the local 
population. Children with arrhythmias or clinical evidence of heart failure were excluded 
from the study. Renal function was determined by eGFR using the Schwartz formula13,40 
and CKD stage was defined according to published definitions.16 
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4.3.2.1. Peripheral blood pressure measurement 
Peripheral systolic (pSBP) and diastolic blood pressure (pDBP) were measured 3 times 
in succession at the brachial artery by a trained observer after children had been seated 
for at least 5 minutes using a calibrated aneroid sphygmomanometer with an 
appropriate sized arm cuff according to British Hypertension Society guidelines. The 
aneroid sphygmomanometer instruments were checked for accuracy annually. 
Hypertension was defined as systolic and/or diastolic BP above the 95th percentile for 
age and height or if the patient was on anti-hypertensive therapy, using the Fourth 
Report Criteria (National High Blood Pressure Education Program Working Group).154 
 
4.3.2.2. Applanation tonometry-derived estimate of cSBP (cSBPRT) at the 
radial artery  
Radial pressure waveforms were obtained from the right wrist over a 10 second period 
by applanation tonometry using a high-fidelity micromanometer (SPC-301; Millar 
Instruments, Houston, TX) and processed by the SphygmoCor device (Atcor medical, 
Australia) [Figure 5].  
 
Radial waveforms meeting the inbuilt quality control criteria of the SphygmoCor device 
were ensemble averaged and converted to a corresponding aortic waveform using the 
inbuilt SphygmoCor generalised radial-to-aortic transfer function (derived in adults) from 






Radial waveforms were calibrated from peripheral brachial measures of pSBP and 
pDBP, from which peripheral MAP was calculated by integrating the radial waveform. 
Transformed radial waveforms (i.e. estimated aortic waveforms) were calibrated from 
these values of peripheral MAP and pDBP to give a radial tononometric estimate of 
cSBP (cSBPRT) calibrated from non-invasive peripheral measures of SBP and DBP. 
 
4.3.2.3. Radiofrequency ultrasound wall tracking-derived estimate of cSBP 
(cSBPCWT) at the carotid artery 
This was performed similar to the invasive study outlined previously. In contradistinction 
to the validation study, the carotid distension waveforms were calibrated using the same 
values of peripheral MAP and pDBP used to calibrate transformed radial waveforms to 
estimate cSBP (cSBPCWT) [Figure 31]. ART.LAB waveform recordings were accepted if 
the SD of maximum distention was <50 m.  
 
cSBPCWT = pDBP  +   pMAP – pDBP  x  Dmax 
      Dmean 
Figure 31: Radiofrequency ultrasound wall tracking-derived estimate of cSBP 
(cSBPCWT) estimated by the calibrated distention waveforms using the peripheral MAP 
and DBP pressure values 
 
In all children, 3 sequential estimates of cSBP were attempted using radial tonometry 
and carotid wall tracking. The brachial BP measurements were performed initially 
followed by measurement of cSBP using ART.LAB and SphygmoCor devices (with 
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order varied but not strictly randomized). All cSBP estimates were obtained following 
calibration with peripheral BP components and thus, errors in the non-invasive 
peripheral measures of SBP and DBP contributed equally to both, radial tonometry and 
carotid wall tracking estimates of cSBP.  
 
4.3.3. Statistics 
Results are expressed as means±SD. Agreement between methods was assessed by 
measuring the Pearson correlation coefficient, mean difference and SD of difference. 
Bland–Altman plots were used to examine systematic bias and random error. In the 
case of the comparison of carotid wall tracking-derived cSBP with invasive 
measurements, a modified Bland-Altman plot was used whereby the reference invasive 
measurement was substituted for the mean of the two methods on the abscissa of the 
Bland-Altman plot. All analyses were performed using SPSS 21.0 (SPSS Inc., Chicago, 




4.4.1. Invasive validation of carotid wall tracking-derived compared to measured 
aortic cSBP 
Of the 9 children studied, 4 were undergoing arteriography to rule out renovascular or 
aortic disease as a cause for hypertension, two had patent ductus arteriosus (PDA) and 
three had other complex congenital heart disease (CCHD). Demographics and blood 
pressure characteristics are shown in Table 9.  
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Table 9:  Subject characteristics including n=9 subjects for the validation study and 
n=84 for the comparison study. 




Number of subjects 9 84 
Age (years) 10.5 ± 5.0 13.2 ± 3.2 
Male, n (%) 5 (44) 43 (51.2) 
Caucasian, n (%) 
Black, n (%) 
Asian, n (%) 









Height (cm) 135.5 ± 25.4 154.6 ± 20.3 
Weight (kg) 35.3 ± 16.6 53.6 ± 22.4 
BMI (kg/m
2
) 18.0 ± 4.0 21.6 ± 6.1 
Controls, n (%) 
CKD Patients, n (%) 








Antihypertensive drugs, n (%) 2 (22) 17 (8) 
pSBP (mmHg) 96 ± 9.4 108 ± 15.1 
pDBP (mmHg) 43 ± 11.0 59 ± 10.2 
cSBP Catheter (mmHg) 90 ± 14.9 - 
cSBP Carotid Ultrasound (mmHg) 94 ± 13.8 90 ± 11.9 
cSBP Radial Tonometry (mmHg) - 90 ± 11.7 
Values are numbers or means ±SD. CKD, Chronic kidney disease; cSBP, central systolic blood pressure; 





Values of cSBPcarotid obtained from carotid distension-derived estimates of cSBP 
(calibrated using MAPinv and DBPinv) were highly correlated with invasive measures, 
cSBPinv (r=0.99; p<0.0001, Figure 32a). Bland-Altman analysis demonstrated a small 
but significant systematic difference which did not vary significantly with cSBPinv. The 
mean cSBPinv was 90 ± 14.9 mmHg and mean cSBPcarotid was 94 ± 13.8mmHg. The 
mean difference (i.e. aortic to carotid amplification), cSBPcarotid – cSBPinv was 3.9 ± 2.5 




Figure 32: Invasive validation of carotid wall tracking-derived compared to measured 
aortic cSBP a. Correlation between central systolic blood pressure (cSBP) measured by 
invasive catheter and carotid ultrasound (r=0.99, p< 0.001). b. The difference between 






4.4.2. Non-invasive comparison of radial tonometry-derived versus carotid wall 
tracking-derived estimates of cSBP 
Of the 84 children studied, 56 (31 boys) had CKD (stages 1, 2, 3 and 4 of CKD in 10, 
21, 20, and 5 respectively) and 14 children with CKD were on antihypertensive 
medication. Thirteen children (6 boys) had hypertension with normal renal function of 
whom 3 were taking antihypertensive medication. Fifteen children (6 boys) were healthy 
control subjects. Characteristics of all subjects are shown in Table 9.  
We obtained 3 sequential carotid wall tracking recordings of adequate quality in 71 
children but radial tonometry recordings meeting SphmoCor quality control criterion 
were obtained in only 52 children, Estimates of cSBP obtained by radial tonometry and 









Figure 33: Non-invasive comparison of radial tonometry-derived versus carotid wall 
tracking-derived estimates of cSBP a. The correlation between cSBP measured by 
carotid ultrasound and radial tonometry (r=0.95, p<0.001); and b. The difference 
between cSBP measured by carotid ultrasound and radial tonometry (mean±SD, 0.71 ± 
3.7mmHg). There is no significant difference in the mean cSBP obtained by both 
devices (p=0.09) 
 
There was no significant difference between cSBP of the children on anti-hypertensive 
medication (n=17) and those without (n=67): 88 ± 11.8mmHg vs. 90 ± 11.7mmHg, 
respectively (p = 0.43). Bland-Altman analysis revealed no significant systematic error 
and no trend for error to vary with mean cSBP. The mean difference cSBPcarotid – 
cSBPRT was 0.71 ± 3.7 mmHg (95% CI = -1.53 to 1.01). Repeatability of measurements, 
for both methods, when using the same brachial systolic and diastolic BP for calibration 
was excellent: the coefficient of variation for repeated measurements was less than 2% 





4.4.3. Peripheral to central amplification  
Values of peripheral and central SBP as measured by both radial tonometry and carotid 
wall tracking are shown in Figure 34. The mean amplification (peripheral-central SBP) 
was 18.3 ± 6.6 and 17.7 ± 7.6 mmHg for radial tonometry and carotid wall tracking, 
respectively. 
 
Figure 34: Peripheral-to-central amplification. Mean and SD peripheral systolic blood 
pressure (pSBP) and central systolic blood pressure (cSBP) measured by radial 
tonometry and carotid ultrasound. There is no significant difference in cSBP measured 
by tonometry and carotid ultrasound. 
 
4.5. Discussion 
To our knowledge this is the first study to examine the accuracy with which central 
aortic systolic pressure can be estimated non-invasively in children. The method that we 
elected to compare to invasive measures, carotid wall tracking, assumes carotid wall 
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distension to be proportional to local intra-arterial carotid pressure and for carotid 
pressure to approximate aortic root pressure.193,194 Theoretically, tonometric 
measurements obtained at the carotid artery would be expected to perform as well as 
carotid wall tracking.172 However, in preliminary studies we found high quality carotid 
tonometric recordings were more difficult to obtain than ultrasound wall-tracking in 
children. We compared agreement between cSBP estimated from carotid wall tracking 
with measured cSBP in a heterogenous group of children in whom central 
haemodynamics would be expected to vary widely. Despite this we observed good 
agreement between estimated and measured central aortic systolic pressures. This 
suggests that, in most children, assumptions relating to carotid wall distension being 
linearly related to local intra-arterial pressure and lack of pressure gradient at peak 
pressure from aorta to carotid are likely to be valid. 
We observed a small difference between carotid-derived and measured cSBP with 
carotid SBP exceeding measured aortic cSBP. This may be due to some aortic-to-
carotid amplification of SBP between the two measurement sites and could be corrected 
for by subtracting 3.9 mmHg from the carotid SBP with validation in a further study. It is 
important to note that we used invasive measures of mean and diastolic pressures to 
calibrate the aortic distension waveform to obtain a pressure waveform. This is the 
usual approach when assessing the accuracy of central systolic pressure determination 
because it removes the confounding effects of error in peripheral blood pressure 
determination.195,196 However, when the method is applied in practice, non-invasive 
measurements of peripheral pressures are required and any inaccuracy in these will 
influence the accuracy of the derived central aortic systolic pressure.197 
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An alternative method (also requiring calibration from peripheral pressure 
measurements) for assessing central systolic pressure employs radial tonometry and a 
radial-to-aortic transfer function. We found that radial tonometry was more difficult to 
perform than carotid ultrasonography in children. The increased success of carotid wall 
tracking compared to tonometry (as assessed by the greater proportion of children in 
whom readings of adequate quality could be obtained) suggests this may be the 
preferred technique in children. However, when high quality recordings with an 
acceptable SD were used, and when the same peripheral blood pressure was used to 
calibrate both radial artery and carotid artery waveforms, we obtained excellent 
agreement between estimates of central aortic systolic pressure derived from the two 
techniques. Thus despite the radial-to-aortic transfer function being derived in adults, 
these results suggests that it holds to a close approximation in children. Whilst at first 
sight this might seem surprising, it is notable that when used to estimate cSBP in adults, 
the exact form of the transfer function does not appear critical and holds despite 
haemodynamic pertubations such as during pacing and vasodilator therapy which may 
to some extent mimic the circulatory state in children as compared to adults.195,197,198 
Amplification of SBP from the aorta to the upper limb in adults is usually in the order of 
10 mmHg but varies with age being greater in younger compared to older adults.155 
Using an oscillometric device Elmenhorst et al.191 reported lower amplification in 
children and young adults aged 8-21 years, than we observed (by approximately 5 
mmHg). However, when the  oscillometric device was compared to the SphygmoCor, by 
Stoner et al.199 cSBP was, on average, 4.5mmHg (95% confidence interval 4.0 to 5.2 
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mmHg) higher, by the oscillometric method. Thus, discrepancies in amplification may 
arise from the different measurement techniques.  
Results of the present study show that in children, including those with and without 
hypertension and mild to advanced CKD, amplification is substantial with a mean 
amplification of ~ 20 mmHg and thus may be relatively more important than in adults. 
Although not all studies have shown a closer association of cardiovascular events with 
central compared to peripheral SBP in adults200, this may be because of limited sample 
size and/or inaccuracies in the measurement of peripheral BP, and target organ 
damage does appear more closely related to central rather than peripheral BP.154 
Results from the present study suggest that estimation of central aortic systolic pressure 
using either carotid wall tracking or radial tonometry will be helpful in determining 
whether central systolic pressure is equally or more important than peripheral blood 
pressure in children compared to adults. However, it should be noted that the absolute 
accuracy of estimation of central aortic systolic pressure will be dependent on that of the 
peripheral blood pressure and that a number of calibration issues remain. These include 
whether to calibrate from peripheral mean and diastolic pressures or from peripheral 
systolic and diastolic pressures and, if calibrating a radial waveform from a brachial 
systolic pressure, brachial to radial amplification.201 Even if there are relatively large 
errors in determination of peripheral blood pressure, we have previously shown that 
radial tonometry provides a reasonable estimate of the difference between peripheral 
and central systolic pressure.197 Non invasive estimates of cSBP in children obtained by 
either carotid wall tracking or radial tonometry should, therefore, be useful in 
determining: a) factors influencing amplification; b) whether measurement of central 
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aortic systolic pressure provides incremental value over pSBP when assessing target 
organ damage and c) interventions that have differential effects on central and 
peripheral systolic pressure. 
4.5.1. Perspectives 
This study provides data validating non-invasive measurement of central systolic blood 
pressure in children. Systolic pressure amplification in children is almost twice the levels 
of amplification described in adult cohorts and therefore likely to be more clinically 
relevant. Due to the small sample size of the invasive study results need to be 
interpreted with caution and further invasive validation is required. Further work should 
also investigate the factors determining amplification in children and whether measures 
of central blood pressure offer incremental value over peripheral blood pressure in the 



















Chapter 5 : Decreased arterial 
elasticity in children with 
nondialysis chronic kidney 
disease relates to blood pressure 










5.1.  Background 
In adults with chronic kidney disease (CKD), including those with onset of CKD in 
childhood, adverse cardiovascular outcomes are closely related to arterial stiffening.202-
204 Arterial stiffening relates to the severity of CKD, being greatest in those with dialysis 
dependent CKD, and is thought to be driven, at least in part, by metabolic changes 
associated with CKD.120,205,206 To what degree such change occurs early in childhood is 
unknown but could contribute to the greatly increased cardiovascular mortality and 
morbidity in young adults with childhood onset CKD.25,182 
Previous studies in children studying structural and functional properties of large 
arteries have included cohorts of nondialysis CKD, dialysis dependent and children after 
kidney transplantation. Pulse wave velocity (PWV) of the carotid-femoral pathway (i.e. 
mainly the aorta) and/or measures of carotid mechanics have been examined but the 
latter have been limited by lack of concurrent measures of carotid blood pressure 
(required to determine functional elasticity of the carotid artery).107-111 Furthermore, 
whilst the potential impact of age and blood pressure (BP) have been adjusted for, 
when comparing differences between children with and without CKD, this comparison 
has not been performed between age and blood pressure matched groups.  
 
5.2. Objectives 
The objectives of this study were to compare large artery mechanical properties 
including carotid-femoral PWV (PWVcf) and carotid mechanics derived from carotid 
blood pressures in children with non-dialysis CKD and healthy children in an analysis 
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incorporating a case-control design with appropriate matching for age and blood 
pressure and to examine the impact of blood pressure on these measures. 
 
5.3. Methods 
The study was performed at the Evelina London Children’s Hospital (ELCH) UK with the 
approval of the Local Research Ethics Committee. Potential participants were attending 
CKD out-patient clinics and were identified following review of their health records at the 
authors tertiary paediatric nephrology centre serving the South East of England.12 All 
participants included in this study report were enrolled sequentially and included if they 
had acceptable quality of blood pressure and vascular assessments. Written informed 
consent was obtained from parents and children if appropriate. 
A total of 226 children including 188 children with CKD were recruited and 38 healthy 
children from the local population. Inclusion criteria were age 2-18 years, non-dialysis 
CKD irrespective of the presence or absence of hypertension. We excluded children 
with arrhythmias and those with clinical evidence of heart failure. 
Hypertension was defined as systolic and/or diastolic BP above the 95th percentile for 
age and height or if the patient was on anti-hypertensive therapy using the Fourth 
Report Criteria.159 Renal function was estimated using the modified Schwartz 
formula12,13,40, and CKD stage was classified as described previously.16 Eighteen 
healthy children did not have any blood tests, and in them, the average eGFR for 
healthy children was imputed. Clinical markers of mineral bone disease including serum 
calcium, phosphate, calcium-phosphate product (Ca-P), intact parathyroid hormone 
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(iPTH) and (in a sub-sample of n=91) 25-hydroxy vitamin D3 concentrations were 
measured. 
 
5.3.1. Peripheral blood pressure 
Peripheral systolic (pSBP) and diastolic blood pressure (pDBP) were measured 3 times 
in succession at the brachial artery by a trained observer after children had been seated 
for at least 5 minutes using a calibrated aneroid sphygmomanometer with an 
appropriate sized arm cuff according to British Hypertension Society guidelines.  
 
5.3.2. Carotid blood pressure, amplification and augmentation 
Carotid systolic BP (cSBP) was obtained from radial artery tonometry using a transfer 
function and from carotid distension waveforms (with no transfer function). Radial 
pressure waveforms were obtained from the right wrist by applanation tonometry using 
a high-fidelity micromanometer (SPC-301; Millar Instruments, Houston, TX) and 
processed by the SphygmoCor device (Atcor Medical, Australia). Radial waveforms 
were calibrated from brachial measures of pSBP and pDBP, from which mean arterial 
pressure (MAP) was calculated by integrating the radial waveform. Transformed radial 
waveforms (i.e. estimated aortic waveforms) were calibrated from these values of MAP 
and DBP to give a radial tononometric estimate of cSBP (cSBPRT) calibrated from non-
invasive measures of pSBP and pDBP. Operators checked waveform quality and radial 
waveforms were only accepted if in-built quality control measures were achieved. Aortic 
augmentation index (AIx) was derived from the synthesised aortic waveform. cSBP was 
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also derived from carotid waveforms [obtained by echo-tracking as described below, 
(cSBPCWT)] calibrated from MAP and DBP. Amplification of systolic BP (pSBP-cSBP) 
was calculated using cSBPCWT values. 
 
5.3.3. Carotid dimensions and biomechanics 
The right common carotid artery was imaged using the ART.LAB system.171-173 A linear 
transducer (range 4 to 13MHz) was used to image a 4cm segment of artery 
approximately 1 to 5 cm proximal to the flow divider. Mean carotid intima medial 
thickness (IMT) was obtained from automated analysis of the posterior wall over this 
segment of the artery. Radiofrequency wall-tracking was used to obtain distension 
waveforms averaged over 6 cardiac cycles. Diastolic internal lumen diameter (Dd), 
systolic lumen diameter (Ds) and carotid distension (∆D = Ds - Dd) were derived from 
each distension waveforms (each obtained over 6 cardiac cycles) and averaged over 3 
such waveforms. The following measurements/indices of geometry and elasticity as 
described by Laurent et al177 were then derived from these measures of lumen diameter, 
distension and IMT: 
Carotid wall thickness/radius ratio (CWTR) 
   CWTR = 2 × IMT 
                 (Dd+IMT) 
Wall cross-sectional area (WCSA) 
WCSA = π [(Dd+IMT)
2 – Dd
2]  
           4 
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Cross-sectional compliance coefficient (CC), the absolute change in lumen area during 
systole for a given pressure change.   
CC = ∆A 
          PP 
where, ∆A is the change in cross-sectional area (∆A = π∆Dd
2/4) and PP the local pulse 
pressure. 
Cross-sectional distensibility coefficient (DC), the relative change in lumen area during 
systole for a given pressure change. 
DC = (∆ A / A) 
          PP 
where, A is lumen area in diastole (A = πDd
2/4) 
Circumferential wall stress (CWS), calculated using the Lame equation177,178 
CWS = MAP x Dm  
           2 x IMTm 
where, Dm and IMTm are the mean values of internal diameter and wall thickness during 
the cardiac cycle.  
Young’s incremental Elastic Modulus (Einc), elasticity that is independent of the vessel 
geometry. 





5.3.4. Carotid-femoral PWV (PWVcf) 
PWVcf was measured in the supine position using the Vicorder volumetric system 
(Skidmore Medical, UK).  Simultaneous arterial pulse waveforms were recorded using 
pulse volume recording measurements from standard vascular cuffs placed over the 
right carotid artery and the right femoral artery. All measurements were performed 
consecutively three times in succession and the average of three measurements was 
taken. The waveforms acquired at two sites simultaneously gave a transit time (TT) and 
PWVcf calculated from the distance between the suprasternal notch and the top of the 
thigh cuff divided by TT (PWVcf = Distance/TT). 
 
5.3.5. Statistics 
Subject characteristics are expressed as mean ± standard deviation (SD) for continuous 
variables, with two-group comparisons via Student’s unpaired t-test, and three or more 
groups via an analysis of variance (ANOVA) test or Chi-squared test for categorical 
values. Given the age-related change in BP throughout childhood, peripheral BP 
measurements were presented both as mmHg and as standard deviation scores (SDS) 
(the number of standard deviations above or below a population mean assigned a value 
of zero) using published reference values.159 To assess the impact of blood pressure, 
those with CKD were subdivided into subjects with systolic and/or diastolic BP 75th 
percentile and those with systolic and/or diastolic BP <75th percentile. We used the 75th 
percentile for BP as a cut-off based on the results of the ‘ESCAPE’ study which 
suggested that, in children with CKD, achieving a target BP below the 75th percentile 
delays the progression of renal dysfunction.158 The 75th percentile has thus become an 
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important threshold and recommended by the European Society of Hypertension in its 
last guideline.157 Multiple regression analysis was used to examine the relationship 
between measures of arterial stiffness, BP, GFR and other confounders.  Confounders 
were included if they were identified from previous published relevant literature or of 
thought to be of pathophysiological significance and included age, gender, BMI, heart 
rate, anti-hypertensive treatment (yes/no) and biochemical markers of metabolic bone 
disease. Because arterial stiffness may lead to a rise in pulse pressure (PP) and 
systolic BP, the primary analysis was performed using MAP. To examine which 
components of BP were most closely associated with the measures of stiffness, an 
additional analysis was performed in which the MAP, cSBP and carotid PP (cPP) were 
included in a regression analysis. To investigate differences associated with renal 
dysfunction we performed a case-control sub-analysis with 2:1, age (to within 1 year) 
and gender matching (2 CKD subjects for each control), with similar peripheral and 
carotid blood pressure levels. All analyses were performed using SPSS 21.0 (SPSS 
Inc., Chicago, Illinois, USA) and a P-value <0.05 was considered statistically significant. 
 
5.4. Results 
5.4.1. Patient characteristics 
All children with CKD were non-dialysis dependent and none had previously received a 
kidney transplant. There were 49 (26.1%), 47 (25%), 56 (29.8%), 31 (16.5%) and 5 
(2.7%) in CKD stages 1 to 5 respectively.  
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The primary cause of CKD was congenital anomalies of the kidney and urinary tract 
(hypo/dysplasia, obstructive uropathy and vesico-ureteric reflux ± reflux nephropathy] in 
92 (48.9%), glomerular diseases in 43 (22.9%), renovascular disease in 13 (6.9%), 
metabolic renal disease in 14 (7.4%), tubulointerstitial disease in 2 (1.1%), cystic 
diseases (autosomal recessive polycystic kidney disease and nephronophthisis) in 7 
(3.7%) and unknown aetiology in 17 (9.0%) of the cohort. Subject characteristics are 
described in Table 10.  
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Table 10: Characteristics of children according to presence of CKD (n=188) and BP 75th percentile and n=38 controls 
Measures 







Control All (A) BP <75
th
 (B) BP 75
th











   
Age (years) 11.93.7 11.83.5 12.24.2 11.53.3 0.70 0.65 0.43 







172 (76.1%);   
24 (10.6%);  
20 (8.9%);    
10 (4.4%) 
 
108(75%);   
14 (9.7%);  
14 (9.7%);    
8 (5.6%) 
 
36 (81.8%);       
6 (13.6%);        
2 (4.6%);        
0  
 
28 (73.7%);        
4 (10.5%);            
4 (10.5%);            
2 (5.3%) 
0.64 0.46 0.28 
Height (m) 1.470.22 1.470.21 1.460.23 1.490.21 0.77 0.57 0.49 
Weight (kg) 45.619.9 44.418.8 49.423.0 49.223.4 0.22 0.18 0.97 
Height SDS
*
 -0.291.31 -0.231.36 -0.471.16 0.441.26 0.005 0.007 0.001 
Weight SDS
*






















All (A) BP <75
th










6433.8 63.934.8 64.330.4 104.59.0 <0.001 <0.001 <0.001 
Antihypertensive 
drugs, n (%) 
63 (27.8%) 47 (33.5%) 16 (80%) 0 <0.001 <0.001 <0.001 
Serum Calcium  
(mmol/L) 
2.330.10 2.340.10 2.310.10 2.300.07 0.18 0.20 0.81 
Serum phosphate 
(mmol/L) 












50 (31, 76) 49 (32, 76) 52 (29, 72) 25 (21, 30) 0.10 0.03 0.13 




53 (41, 67) 55 (43, 67) 48 (34, 70) 65 (49, 226) <0.001 <0.001 0.01 
*
SDS, standard deviation score; 
†
BMI, body mass index; 
‡
BSA, body surface area; 
§
eGFR, glomerular filtration rate; 
||
iPTH, intact parathyroid 
hormone; 
¶
median (interquartile range); 
#
measured in subset of sample. 
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Those with CKD were comparable with control children for age and ethnicity. There 
were more boys as compared to girls with CKD, reflecting the usual gender distribution 
of CKD in children. Those with CKD were significantly shorter (p=0.002) but had 
comparable body mass index (BMI) SDS (p=0.46) and body surface area (p=0.38) 
when compared with controls. There were no significant differences in characteristics 
other than BP between those with BP 75th percentile versus BP <75th percentile CKD 
sub-groups (Table 10). A higher proportion of children with stages 3-5 of CKD were on 
anti-hypertensive treatment, a surrogate marker for prior history of hypertension [83% 
(25/30), 72% (13/18) and 80% (4/5)] compared to children in stages 1-2 of CKD [26% 
(10/39) and 31% (11/36)] respectively. The CKD sub-groups were also comparable for 
markers of mineral bone disease including serum calcium, phosphorus and Ca-P 
product and iPTH. Vitamin D3 concentrations were significantly lower in children with 
CKD when compared with controls. 
 
5.4.2. Peripheral and carotid BP and pulse wave analyses 
Children with CKD and BP <75th percentile had similar peripheral and carotid BP to 
normotensive control children, whereas those with BP 75th percentile had significantly 
higher peripheral and carotid systolic and diastolic BP but not pulse pressure (Table 
11). Carotid AIx was also significantly higher in the children with CKD and BP 75th 
percentile compared to normotensive controls but similar in children with and without 
CKD in whom BP was similar.  
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Table 11: Peripheral and carotid blood pressure including n=188 with CKD and 38 healthy controls 
 










versus Control Measures 
All (A) BP <75
th
 (B) BP 75
th
 (C) D B-D 














 7312 699 8612 729 
0.001 0.053 <0.001 





















BP, blood pressure; 
*
pSBP, peripheral systolic BP; 
†
pDBP, peripheral diastolic BP; 
‡
MAP, mean arterial pressure; 
§
SDS, standard deviation 
score; 
||
bpm, beats per minute; 
¶
cSBPCWT, carotid SBP measured using carotid-wall tracking; 
#
cSBPRT, radial tononometric estimate of cSBP; 
**
cPP, carotid pulse pressure; Amplification, pSBP-cSBPCWT calculated as the difference between peripheral and carotid systolic BP; 
^
AIx, 
augmentation index (%) performed using radial tonometry based pulse wave analysis. 
 










versus Control Measures 
All (A) BP <75
th
 (B) BP 75
th
 (C) D B-D 




8914 8510 10217 8811 <0.001 0.13 <0.001 
cSBPRT
#
 8913 858 10414 878 <0.001 0.20 <0.001 
cPP
**
 3213 3211 3120 329 0.91 0.83 0.84 
Amplification 166 154 199 154 0.01 0.52 0.03 
AIx (%)
^
 513 413 913 0.411 0.04 0.12 0.01 
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5.4.3. Carotid dimensions and biomechanical properties 
Carotid lumen and wall dimensions were similar in all groups. By contrast, 
circumferential wall stress and functional measures of arterial stiffness differed between 
children with CKD and BP 75th percentile compared to normotensive controls but not 
between children with and without CKD in whom BP was similar. Thus circumferential 
wall stress and Young’s elastic modulus were significantly greater and cross-sectional 
distensibility and compliance coefficient were significantly lower in children with CKD 
and BP 75th percentile than in controls (Table 12, each P<0.05). Thus, the anatomy of 
the carotid artery was maintained and functional elastic properties of the wall were 
impaired only in children with CKD in whom BP was greater than in those without CKD. 
There was no significant difference between subgroups by CKD stage for any carotid 
biomechanical property evaluated. 
 
5.4.4. Carotid-femoral PWV 
PWVcf was similar in all 3 groups: 5.34  0.82, 5.24  0.83 and 5.50  1.11 m/s in 
healthy normotensive control children, those with CKD and BP < 75th percentile and 





















All (A) BP <75
th
 (B) BP 75
th
 (C) D B-D 












0.23 0.48 0.48 
Anatomical measures 












0.78 0.59 0.90 



























0.83 0.67 0.58 


































All (A) BP <75
th
 (B) BP 75
th
 (C) D B-D 








0.65 0.37 0.46 
Functional elasticity measures 












































0.06 0.13 0.02 













0.04 0.14 0.02 
+
BP, blood pressure; 
†




PWV, pulse wave velocity
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5.4.5. Relation of indices of carotid stiffness to blood pressure, eGFR and other 
characteristics  
In all children with CKD, indices of elasticity except circumferential wall stress were 
independently related to age. Compliance was additionally related to MAP and 
circumferential wall stress to BMI. However, none of the indices of elasticity were 
independently related to GFR (Table 13).  
 
Table 13: Multiple linear regression analysis of correlates of functional elasticity with 
brachial mean arterial pressure in children with non-dialysis CKD (n=88) 




























































Confounders in all models included MAP (not included in circumferential wall stress), GFR in 
ml/min/1.73m
2





There were no significant differences in arterial measures between boys and girls 
(Table 14).  
 
Table 14: Comparison of arterial measures by gender in healthy children (n=38) and 






Male Female P value Male Female 
P 
value 





 101.6 4.9 106.0 10.2 0.154 61.5 31.2 68.2 37.4 0.187 
MAP (mmHg)
†
 74 10 70 8 0.257 72 12 73 12 0.639 
cSBPCWT (mmHg)
 ‡
 92 11 86 10 0.154 88 14 89 13 0.800 
Circumferential wall 
stress (kPa) 


























0.1200.030 0.1040.056 0.438 0.1330.067 0.1300.048 0.807 
+
CKD, chronic kidney disease; 
*
eGFR, glomerular filtration rate; 
†
MAP, mean arterial pressure; 
‡
cSBPCWT, 







The relative impact (sequential R2 coefficient) of age, gender, CKD or control group and 
MAP on arterial measures is shown in Table 15.  
 
Table 15: Multivariate analyses with sequential R2 changes for arterial measures 
showing the relative influence of age and mean arterial pressure following adjustment 
for gender and CKD (n=88) or control group (n=38) 
Arterial 
parameter 






wall stress (kPa)   
Age 1.717 <0.001 0.112 0.105 
 
     
 Age 1.736 <0.001 0.116 0.101 
 Sex -2.193 0.459   
      
 Age 1.768 <0.001 0.119 0.096 
 Sex -1.791 0.555   
 CKD*/ control group 2.19 0.533   
      
Cross-sectional 
Distensibility (kPa-
1 x 10-3)  
Age -4.569 <0.001 0.167 0.16 
      
 Age -4.565 <0.001 0.167 0.153 
 Sex -0.467 0.941   
      
 Age -4.474 <0.001 0.173 0.151 
 Sex 0.691 0.914   
 CKD/ control group 6.372 0.391   
      
 Age -4.86 <0.001 0.178 0.149 
 Sex 0.889 0.89   
 CKD/ control group 6.345 0.394   
 MAP
†
 0.248 0.416   
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Arterial 
parameter 







kPa-1 x 10-6)  
Age -0.046 0.025 0.042 0.034 
 Age -0.046 0.024 0.046 0.029 
 Sex 0.083 0.532   
      
 Age -0.042 0.039 0.075 0.051 
 Sex 0.137 0.31   
 CKD/ control group 0.296 0.059   
      
 Age -0.069 0.002 0.135 0.105 
 Sex 0.151 0.25   
 CKD/ control group 0.294 0.054   
 MAP 0.017 0.006   
      
Young's Elastic 
Modulus (kPa x 10
3
) 
Age 0.007 <0.001 0.168 0.161 
      
 Age 0.007 <0.001 0.172 0.157 
 Sex 0.007 0.47   
      
 Age 0.007 <0.001 0.184 0.163 
 Sex 0.005 0.65   
 CKD/ control group -0.015 0.194   
      
 Age 0.008 <0.001 0.197 0.168 
 Sex 0.004 0.689   
 CKD/ control group -0.015 0.198   
  MAP -0.001 0.188     
*
CKD, chronic kidney disease; 
†
MAP, mean arterial pressure; ^CS, cross-sectional 
 




Table 16: Results of multivariable regression analyses of relevant functional elastic 
carotid artery parameters with brachial mean arterial pressure, carotid systolic BP and 
carotid pulse pressure in n=88 children with CKD. A separate model was constructed for 
each blood pressure component and adjusted with the same confounders throughout 
(as shown in Table 13). Coefficients for the different components of peripheral and 
carotid pressure are shown from each of the models (coefficients for confounders not 
shown) 
Variable Coefficient SE P Model adjusted R
2
 
Circumferential wall stress  (kPa) 
Mean arterial pressure (mmHg) 
- - 
- - 
Carotid systolic BP (mmHg) 0.821 0.131 <0.001 0.379 
Carotid pulse pressure (mmHg) -0.359 0.248 0.152 0.097 





Mean arterial pressure (mmHg) 0.518 0.441 0.245 0.096 
Carotid systolic BP (mmHg) -0.198 0.443 0.657 0.078 
Carotid pulse pressure (mmHg) - - - - 







Mean arterial pressure (mmHg) 0.016 0.008 0.046 0.112 
Carotid systolic BP (mmHg) 0.001 0.009 0.885 0.010 
Carotid pulse pressure (mmHg) - - - - 
Young's Elastic Modulus (kPa x 10
3
) 
Mean arterial pressure (mmHg) -0.001 0.001 0.084 0.078 
Carotid systolic BP (mmHg) 0.0001 0.001 0.811 0.030 




On multiple regression analysis to examine the relationship of PWVcf and eGFR 
following adjustment for confounders [including MAP, age, gender, BMI, heart rate and 
anti-hypertensive treatment (yes/no)], age alone maintained a significant positive 
relationship with PWVcf (β=0.423, p=0.003) but there was no significant relationship 
between eGFR and PWVcf (β=0.113, p=0.33); model r2=0.385. 
 
5.4.6. Case control analysis 
In the case-control analysis there was a significant difference in GFR between the CKD 
and control group (54.3± 17.7 vs. 103.5± 8.5 ml/min/1.73m2, p<0.001). Despite this 
marked difference in GFR, measures of arterial stiffness were similar in age and gender 











Table 17: Case control analysis of age and gender matched CKD children (n=58) with 
healthy controls (n=29), with similar peripheral and carotid BP levels 
Measures Controls CKD P value 
Number (%) 29 58  
Age (years) 
11.8± 3.4 11.7± 3.4 0.944 





 103.5± 8.5 54.3± 17.7 <0.001 
Height SDS
†





 0.56±1.44 0.71±0.99 0.622 
pSBP
§
 103± 11 102± 11 0.957 
pDBP
||
 56± 10 55± 11 0.838 
MAP
¶
 71± 8 71± 10 0.863 
Pulse pressure 47± 13 47± 9 0.891 
SBP SDS -0.39±0.75 -0.36±0.91 0.88 
Antihypertensive drugs, n (%) 0 18 (31%) <0.001 
Heart rate (bpm)
 #
 76± 13 74± 13 0.61 
cSBPCWT
**
 88± 11 87± 11 0.803 
Carotid-femoral PWV (m/s)
^
 5.40.9 5.50.9 0.695 
Internal diastolic diameter (m x 10
-3
) 5.52±0.57 5.39±0.45 0.32 








Measures Controls CKD P value 
Intima-media thickness (m x 10
-6
) 434±62 443±53 0.542 





8.3±1.9 8.1±1.3 0.749 
Thickness / radius ratio (h/r) 0.135±0.014 0.142±0.016 0.112 





) 113±35 105±36 0.405 






) 2.7±0.8 2.4±0.6 0.092 
Young's Elastic Modulus (kPa x 10
3
) 0.109±0.053 0.124±0.041 0.233 
*
eGFR, glomerular filtration rate; 
†
SDS, standard deviation score; 
‡
BMI, body mass index; 
§
pSBP, 
peripheral systolic BP; 
||





To our knowledge, this is the first study to provide a comprehensive characterization of 
arterial biomechanics in children with CKD. Our main findings are novel and twofold, (i) 
when children with nondialysis CKD are compared with healthy children with normal 
renal function, at similar levels of peripheral and carotid blood pressure, anatomical and 
functional elastic properties of the large arteries such as lumen diameter, wall thickness, 
PWVcf and elastic modulus remain comparable; but (ii) when children with CKD and 
sub-optimal BP control (75th percentile) are compared with normotensive controls there 
are significant differences in functional elastic properties of the carotid artery. 
Furthermore, we found no independent relationship between any biomechanical 
property and GFR when age, gender and blood pressure (both peripheral and carotid) 
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were adjusted for, nor a difference between biomechanical properties in children with or 
without CKD using an age and gender case control analysis in children with similar BP. 
This suggests that blood pressure rather than renal disease per se is the main 
determinant of functional arterial elasticity in children with predialysis CKD. 
These findings contrast with previous studies that have reported structural and 
functional changes including increased arterial wall thickness, increased arterial wall 
cross sectional area and stiffness107-111 in children with CKD compared to healthy 
controls. Children with predialysis stages of CKD in these studies had abnormal 
mechanical arterial measures that were associated with increased BP, dyslipidaemia 
and markers of mineral bone metabolism107,108,111, with stronger associations in subjects 
on dialysis107-111. Metabolic derangements associated with mineral bone disease in CKD 
are well known to contribute to arterial calcification and could explain the changes seen 
in children with advanced CKD.207 Mitsnefes et al have reported that, in a group of 
children with CKD, including children on dialysis, carotid IMT and arterial stiffness are 
associated with disturbances of Ca-P metabolism and hyperparathyroidism.108 In this 
study children with predialysis CKD had increased carotid IMT and measures of arterial 
stiffness compared to control children but this may have been explained by BP which 
was higher in children with pre-dialysis CKD compared to controls. Thus their results 
are consistent with those of the present study.  
However, Briet et al compared biomechanical properties of the carotid artery to (similar 
to those measured in the present study) in adults with CKD with those in patients with 
hypertension (but without CKD) and healthy controls.206 Their main finding was that, 
compared to controls with similar levels of blood pressure, patients with CKD had an 
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outward remodelling of the carotid artery with enlargement of the lumen diameter 
predominating over carotid wall thickening and stiffening. This may be a response to 
increased wall stress, which together with carotid diameter was independently related to 
age, blood pressure and GFR. The present study, by contrast, reveals no evidence of 
any form of remodeling in children with pre-dialysis CKD who, compared to adults, 
usually have a shorter duration of both hypertension and CKD. We did observe higher 
wall stress in the CKD group with higher blood pressure compared to normotensive 
controls (explicable by the difference in blood pressure alone) but, even in this group, 
there was no evidence of remodelling. This may reflect a relatively short duration of 
hypertension in children with CKD. Were hypertension sustained, this persistent 
increase in circumferential wall stress might result in arterial remodelling as described 
by Briet et al.206 
Other studies have demonstrated childhood blood pressure to predict increased arterial 
stiffness in adulthood.208-210 In the Young Finn’s study reduced carotid arterial 
compliance and increased Young’s elastic modulus was predicted by increased systolic 
BP and skinfold thickness/ BMI during childhood.210 Findings with respect to PWVcf 
have been more variable with an association of adult PWVcf with childhood BP reported 
in the Bogalausa208 but not in the ARYA study.209 It is possible that Young’s elastic 
modulus is a more sensitive index of susceptibility to the influence of BP than is PWV 
(which is proportional to the square root of E) and this would be consistent with findings 
in the present study where we observed increased Young’s elastic modulus in the 
carotid but not increased PWVcf in children with CKD and higher blood pressure 
compared to controls. It is also possible that, as a more muscular artery, the carotid 
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artery is more susceptible to BP induced remodeling that the aorta (the major 
contributor to PWVcf). We observed higher AIx and reduced elasticity but similar PWV 
in those with CKD and sub-optimal BP when compared with healthy controls and CKD 
with optimal BP levels. This increased stiffness though was not accompanied by an 
increase in pulse pressure. This could be due to differential remodelling of arteries of 
different structure (muscular carotid versus elastic aorta) and might also reflect the 
result of treatment with anti-hypertensive medication, with more patients on treatment 
for hypertension with worsening stages of CKD.      
In healthy children, both BP and BMI track throughout childhood and subsequently as 
young adult.211,212 In children with CKD, BP control deteriorates with worsening renal 
function213,214 and both BP and BMI increase following transplantation from pre-
transplantation levels.46,215-217 We would suggest, therefore, that persistently high BP 
and BMI in children with pre-dialysis CKD is likely to lead to increased functional 
stiffness of the carotid artery. Blood pressure reduction may be an effective means to 
protect against arterial stiffening and/or remodeling in children with CKD and 
hypertension that persists into adulthood. In the present study we found no association 
of arterial properties with metabolic derangements. However, phosphate was well 
controlled in the children in the present study. In children with more advanced CKD, 
particularly those on dialysis it is likely that metabolic derangements contribute to 
arterial stiffening and in this case blood pressure reduction may be of more limited 
value. 
We did not perform any formal sample size estimates to investigate an association of 
eGFR with measures of arterial remodelling evaluated here. This was because there 
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was limited data regarding this in children with pre-dialysis CKD at the time of study 
commencement. Data from adult studies is arguably not applicable to a childhood 
cohort, since adults with CKD often have more severe and more long-standing 
hypertension and additional co-morbidities including diabetes, smoking and 
dyslipidaemia.206 Available data from such adult cohorts highlights the limited influence 
of GFR on arterial properties including Young’s Elastic modulus (2%) and carotid 
arterial diameter (3%). An important limitation of our study was that we had relatively 
33.8 ml/min/1.73m2) and 
therefore our results do not preclude an association of arterial remodeling with GFR in 
children with more severe CKD. 
The main limitation of our study is its cross-sectional nature that limits conclusions 
regarding causality. Limitations of the analyses include defining hypertension as a 
categoric variable (yes/no), with lack of data regarding duration of hypertension and of 
severity of hypertension (indicated by need for 2 or more anti-hypertensive agents). 
Nearly a third of children with CKD were receiving anti-hypertensive therapy (usually as 
monotherapy in the form of angiotensin converting enzyme inhibitors, ACEi). It is 
possible that ACEi may impact on arterial properties, although sub-group analyses did 
not suggest a specific effect of treatment. We acknowledge though that it remains 
difficult to discount the inherent confounding in this cohort particularly from treatments 
causally associated with CKD. However our results are applicable to the children with 
CKD representative of those in the general population with CKD (in whom a similarly 





This study provides data that changes in functional elastic properties of the carotid 
artery are some of the earliest identifiable biomechanical properties in children with non-
dialysis CKD. We observed no changes in carotid lumen and wall dimensions, findings 
that are in contrast to previous studies.  These changes appear to be related primarily to 
BP and not GFR or markers of mineral bone disease. Due to the smaller number of 
subjects with more advanced stages of CKD these findings need further testing in a 
larger cohort with advanced CKD. Blood pressure reduction may be an effective means 




















Chapter 6 : The Hypertension 
Optimal Treatment in Children with 
Chronic Kidney Disease study: 
The HOT-KID study- protocol of a 
randomised trial to compare 
effects of aggressive versus 
standard targets in blood pressure 
on target organ damage in 






6.1. Background  
Despite a strong association between left ventricular mass, IMT and arterial stiffness 
with blood pressure in adults with CKD120,218,219, the role of blood pressure in 
determining target organ damage in children with CKD remains controversial. Although 
there are increasing data regarding IMT and arterial stiffness, in children with CKD the 
association of IMT with blood pressure remains unclear.105,107-117. In children with 
dialysis dependent CKD, both LVH and arterial stiffness are thought to be determined 
less by blood pressure and more by other mechanisms such as hyper-parathyroidism 
leading to myocardial hypertrophy and arterial stiffening through calcification.54,107-111,123 
In children with predialysis CKD, the relationship of blood pressure with LVH continues 
to remain unclear following initial reports from the two largest multi-centre study reports, 
with one from Europe54 and the other from the United States of America43 showing 
conflicting relationships. The larger observational dataset from the multi-centre North 
American ‘CKiD study’ reported a significant association of elevated BP with LVH.43 In 
contrast, the multi-centre European trial, the ‘ESCAPE’ study was designed to evaluate 
the reno-protective efficacy of intensified blood pressure control in paediatric patients 
with predialysis CKD.158 The authors reported a significant reduction in renal failure 
progression in patients who had intensified blood pressure control (<50th percentile) as 
opposed to conventional BP control (50th-95th percentile). The ESCAPE study was not 
designed to evaluated the effects of aggressive versus standard BP control on LV mass 
or on arterial structure and function158, but the investigators published an analyses on 
the study cohort at baseline and reported no association between LVH and BP but a 
significant association with male gender, anaemia, increasing weight, 
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hyperparathyroidism and reduced GFR.54 Further recent reports from these two cohorts 
now suggest a more significant role of BP.41,44 The CKiD longitudinal studies suggest 
systolic BP, female gender, anaemia and use of anti-hypertensive medications other 
than RAAS inhibitors of to be predictive of LVH in those with nondialysis CKD.44 The 
ESCAPE investigators on longitudinal study in a limited subset of n=84 subjects, were 
not observed to have the same impact of improved BP control on LVH but a 
predominant impact on LV function independent of BP control.41  
In our paediatric predialysis CKD population at the Evelina London Children’s Hospital, 
we have observed a significant association between LVH and blood pressure (Figure 
35).40 Despite having clinic BP measurements consistently within the currently accepted 
normal range (below 90th percentile) there was a significant difference in BP between 
those with and without LVH (Figure 36). Thus, in our own study, we have found a 






Figure 35: Relationship of clinic systolic BP z-score with indexed LV mass in all patients 
 
 
Figure 36: Clinic systolic BP z-scores in children with chronic kidney disease stage 3-5 
patients with and without left ventricular hypertrophy (LVH). Interrupted line at the 90th 
and 95th percentile denotes the clinical definition of pre-hypertension and hypertension. 
Data shown as mean ± SEM 
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 Our findings are at variance with the ESCAPE study both with regard to the finding of a 
positive association of LVH with BP and lack of an association with male gender, 
anaemia, inflammation, ponderosity or hyperparathyroidism.54 The strong correlation of 
blood pressure with LVH in our own population may in part be because all blood 
pressure measurements were performed by the same observer using auscultation with 
mercury sphygmomanometer or calibrated aneroid instruments. When using 24-hour 
ambulatory BP monitoring (ABPM) we (and the CKiD investigators)43 included all 
measurements as opposed to only a proportion of measurements (as in the ESCAPE 
study). We have previously shown that using a subset of the ABPM is likely to introduce 
significant clinical errors in the interpretation of ABPM.220 These differences may also be 
because of the difficulties in the measurement of blood pressure and the definition of 
“hypertension” during childhood as a categorical state with a value of systolic blood 
pressure above the 95th percentile for the population.221,222 
Overall, though our data suggest that even in those with blood pressure below the 90th 
percentile, blood pressure may still be responsible for at least a component of LVH. The 
association of LVH with systolic BP in the absence of overt hypertension, suggests that 
current targets for BP control should be re-evaluated in this population.40 Extrapolation 
from data in adults with and without CKD suggests that the same may be true for IMT 
and arterial stiffness.  
Commonly reported measures of end organ damage include measures of arterial 
stiffness and left ventricular hypertrophy, which in adults with CKD relate strongly to BP. 
Improved management of hypertension is a key aspect of management of adult CKD 
patients with recommendations for more stringent blood pressure targets in adults with 
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proteinuric CKD.156 There are no current guidelines regarding optimal level of blood 
pressure control for cardiovascular outcomes in children with CKD.157 Until recently, 
recommendations for children with CKD were to maintain BP below the 90th percentile 
for the child’s age, gender and height.159 Based on the findings of the ESCAPE study158, 
the European Society of Hypertension now recommend maintaining BP below the 75th 
percentile primarily to retard progression of renal failure.157 Our findings of a high 
prevalence of LVH in children with CKD and BP below the 90th percentile, together with 
the experience in adults, raises the important question of whether even this target for 
children with CKD is too high.  
An additional consideration in children with CKD is the potential importance of central 
systolic blood pressure. Because of the limitations of cross-sectional association 
studies, optimal hypertension control can only be answered by a randomised 
interventional trial. We propose testing the benefit of maintaining blood pressure below 
the 40th percentile on cardiovascular target organ damage by a controlled trial: 
‘Hypertension Optimal Treatment in Children with Chronic Kidney Disease study: The 
HOT-KID study- a randomised trial to compare effects of aggressive versus standard 
targets in blood pressure on target organ damage in children with CKD’.  
The HOT-KID study is designed to provide important definitive evidence of whether a 
lower than currently recommended level of clinic blood pressure ameliorates adverse 





6.2. Methods/design  
Study overview shown as a flow chart in Figure 37. 
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Informed consent discussion process 
Annual review following baseline assessment 
Clinic BP, Central BP, heart ultrasound, vascular studies, blood and urine tested and stored 
Lower blood pressure level  
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Our primary objectives in this trial are to  
1. a) Examine the relationship of LVM, IMT and arterial stiffness to blood pressure 
(following adjustment for confounders) in a cohort of children with and without CKD.  
b) Compare these measures in children with and without CKD when adjusted for 
peripheral and central blood pressure.  
2. Perform a randomised controlled trial to determine whether aggressive blood 
pressure reduction (below the 40th percentile) compared to standard care (below the 
75th percentile) is effective in normalising left ventricular mass and arterial 
structure/function. 
The secondary objectives are to examine the effects of aggressive versus standard 
blood pressure reduction on microalbuminuria and progression of renal failure and to 
determine if biomarkers of arterial injury/ventricular load are independently related to 
cardiovascular target organ damage. 
 
6.2.2. Study design 
The HOT-KID study is designed as a phase III randomised parallel group controlled 
non-blinded trial. Subjects randomised to the trial will be assigned to one of two arms: 
intervention arm where clinic SBP will be maintained <40th percentile and standard arm 
with SBP maintained between 50th-75th percentile for age and height. The trial subjects 





Children with CKD under the care of a paediatric nephrologist will be recruited from 14 
centres including 11 of 13 tertiary paediatric nephrology centres in the UK thus 
representing the national childhood CKD population. Potential subjects meeting 
eligibility criteria will be identified from clinic lists and departmental databases following 
which their suitability for participation in the trial will be discussed with their lead 
clinician. Estimated GFR (eGFR) will be calculated using the Schwartz formula and 
CKD staged as per existing definitions.13,14,16 Study information sheets outlining the 
study will be mailed to the parents or guardians of potentially eligible children (and the 
child where age appropriate), 2 to 4 weeks prior to their next clinical appointment. At the 
time of this appointment, a member of the research team will discuss the study in further 
detail and confirm eligibility with regard to inclusion and exclusion criteria (as below). 
Informed consent will then be sought from the parents (or guardians) and subjects 
(informed consent or assent according to age) either at the time of this review or at the 
time of their next clinical review once the child and family have had an opportunity to 
consider and discuss the study information. 
Subjects recruited in external centres will await a ‘research study visit’ for cardiac and 
vascular baseline investigations and subsequent randomisation. Thus, any intervention 
as part of the research study will commence only following baseline investigations. All 
cardiac and vascular investigations described in this study will be performed by core 
group of study investigators at the ELCH or at participating external centres.  Children 




6.2.4. Selection and withdrawal of subjects 
 
6.2.4.1. Inclusion criteria 
 Age 2 to 15 years  
 Chronic kidney disease, stages 1-4 of CKD   
 Children with or without antihypertensive/s medications (including any recent 
change/s in antihypertensive therapy).  
 Children on anti-hypertensive medications must be able to tolerate either an 
Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker 
(ARB) medication.   
 Children with average clinic systolic BP <50th percentile and on no antihypertensive 
medication will be eligible as ‘CONTROL-CKD’ and  
 Children with no renal disease, normal renal function and blood pressure will be 
eligible as ‘CONTROL-HEALTHY’  
 
6.2.4.2. Exclusion criteria 
 Age <2 and >16 years  
 Children who have/have had an arterio-venous fistulae 
 Children who are on/have had chronic maintenance dialysis  
 Children who have/have had a functioning kidney transplant 
 Children with symptomatic BP or with past history of difficulty to control BP or  
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 Children in whom there is a clinical urgency to treat BP and inclusion in study may 
result in possible delay of treatment 
 Children with arrhythmia or clinical heart failure 
 Children with a known structural cardiac abnormality 
 Children on treatment with angiotensin converting enzyme inhibitor (ACEi) or 
angiotensin receptor blocker (ARB) agents for treatment of proteinuria only or  
 Children who are likely to be of clinical concern following up or down titration of BP 
levels as described later in section 6.2.6  
 Children who are unable or intolerant to perform study related measurements e.g. 
height, echo or PWV 
 Children who have/have had intolerance to ACEi and/or ARB drug/s or have any 
existing contraindications 
 
6.2.4.3. Withdrawal of subjects 
 Children will stop participating in the study if their eGFR <15 ml/min/1.73m2 or if they 
commence renal replacement therapy (dialysis or transplantation).  
 Children will be withdrawn if they are unable to tolerate the performance of study 
related measurements e.g. height, echo or PWV or if they develop concerning 
adverse effects as a result of ACEi or ARB class of anti-hypertensive medications.   
 If a child wishes to withdraw from the study this will be allowed. Identifiable data 
already collected with consent would be retained and used in the study. No further 
data or tissue would be collected or any other research procedures carried out on or 
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in relation to the participant. In principle we would aim to keep blood and urine 
specimen and data gathered up to the point that the consent is lost. However as 
patients are continually followed up by the clinical team we will be able to determine 
if the patient wants us to withdraw their data from the study. We will always follow 
the patient and their families’ wishes. 
 
6.2.5. Randomisation and allocation result dissemination 
Study related investigations at ‘baseline’ will be performed before subjects are 
randomized. Subjects will be randomised to the two arms of the study: aggressive BP 
control (below the 40th percentile) or standard BP control (between 50th-75th percentile). 
Randomisation will be performed using an online platform at the the Institute of 
Psychiatry Clinical Trials Unit, Kings College London (IoP CTU KCL). The 
randomization will be stratified per centre to ensure matching of number of subjects to 
two trial arms. The results of randomization are not blinded and will be informed to their 
clinical teams.  
 
6.2.6. Blood pressure targets and drug therapy 
Following randomisation all subjects in whom systolic blood pressure is not to target will 
be reviewed at 2-4 weekly intervals. Up or down titration of blood pressure during the 




















Figure 38: Schematic representation of up and down titration of blood pressure during 
the trial following randomisation – standard or intervention (aggressive) trial arm. 
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Once BP is to target, randomized subjects will be monitored at least 4-monthly at the 
time of routine hospital visits and have clinic BP maintained in the assigned target range 
over the duration of the study. The target BP will be titrated to the subject’s age at 
annual intervals.  
Patients already on anti-hypertensive medications at the time of study entry will 
continue on these or change as per clinical indication. ACEi or ARB’s will be the 
recommended first line agents. The dose of the agent will be adjusted to achieve the 
target blood-pressure levels with initial follow up at 2-4 weekly intervals following 
commencement of medication. The following order of escalation will be used (1) calcium 
channel blocker (CCB) (2) beta-receptor blocker (3) others such as diuretic or an alpha 
channel blockers. The preferential use of long acting drugs with once daily dosing is 
recommended. This order of escalation will be used unless there are clear clinical 
indications for other agents. Amendments to the ‘BP titration’ procedures (Figure 38) 
will be made if necessary following review of data after 20 subjects. 
 
6.2.7. Study assessments 
Following initial entry into the study a detailed history will be taken and case records 
reviewed to determine the cause and duration of CKD, past and family history relevant 





6.2.7.1. Assessments at annual intervals  
The following will be performed at baseline and subsequently at annual intervals for the 
duration of the trial in all subjects including those randomized and controls.  
 
6.2.7.1.1. Clinical characteristics, examination and anthropomometry  
The clinical history will be updated together with details of current medications including 
antihypertensive treatment, phosphate binders and hydroxylated vitamin D. A clinical 
examination will be performed. Height (stadiometre), weight and body mass index (BMI) 
will be recorded.  
 
6.2.7.1.2.  Urinanalysis 
Urine samples will be collected at baseline and at annual intervals. First morning voids 
on the three days prior to clinic visit will be required. The patient will keep urine 
specimens in a home refrigerator at 4OC before clinic visits. Specimens will be stored at 
-80OC. A mean value of three Ualbumin/Ucreatinine will be recorded. 
 
6.2.7.1.3. Biochemistry 
Blood biochemistry will be performed at baseline and at annual visits. In addition to 
serum urea, electrolytes, creatinine and cystatin C, the following biomarkers related to 
arterial injury, calcification and ventricular load will be determined: 
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a) Arterial injury: lipid profiles (total cholesterol, LDL-cholesterol, HDL-cholesterol, 
triglycerides and Apoliporotein-B), homocysteine, high sensitivity CRP.  
b) Arterial calcification: plasma calcium, plasma phosphate and calcium-phosphate 
product (Ca*PO4), plasma intact parathyroid hormone (iPTH), fibroblast growth factor 
23 (FGF23), 25(OH) vit D, 1,25 (OH) vit D, blood haemoglobin (Hb).  
c) Ventricular load and injury: N-terminal pro-B type natriuretic peptide (NT-proBNP), 
high-sensitive cardiac Troponin T (hs-cTnT). 
 
6.2.7.1.4. Peripheral and central blood pressure 
 
6.2.7.1.4.1. Clinic blood pressure 
Peripheral BP will be taken as the mean of 3 measurements using appropriate sized 
cuff and a calibrated aneroid instrument according to British Hypertension Society 
guidelines. All observers will undergo appropriate training including the evaluation of 
their variation from independent experienced investigators. Normative criteria will be 
those defined in the Fourth report of the National High Blood Pressure Education 
Program Working Group in the United States (‘Fourth report’)159 and BP will be 






6.2.7.1.4.2. Ambulatory BP monitoring (ABPM) over 24-hours  
The performance of 24-hour ABPM is not mandatory but it is likely that for clinical 
reasons some children with CKD will have ABPM studies performed during the trial. 
Thus, in a subset of subjects both clinic and ABPM monitoring data will be available for 
analyses. ABPM studies will be performed in patients > 5 years and > 120 cm using 
Spacelabs 90217 oscillometric ABP devices (Spacelabs Inc, Redmond, Wash, USA). 
Measurements will be performed once every 30-minute throughout the period of 
monitoring. Daytime and nighttime periods during each ABP recording will be defined 
using information in the patient ‘ABPM diary card’.220 An ABPM study will be judged to 
be of poor quality and excluded if (1) if there are more than 3-hours of interrupted 
recordings at any time during the 24-hour period; (2) if the duration of ABPM recording 
is inadequate and less than 20-hours in total, less than 12-hours continuously or does 
not include any nighttime measurements.40 All mean ABPM parameters will be analysed 
as z-scores using the normative limits as per Wuhl et al.223  Nocturnal systolic and 
diastolic dipping status will be defined as a reduction in nighttime systolic (or diastolic 
BP) of greater than 10% of the daytime systolic (or diastolic) BP. All ABPM studies will 
be analysed centrally at the ELCH. 
 
6.2.7.1.4.3. Central blood pressure 
Central blood pressure will be estimated both from radial tonometry and modified BP 
measurement using a brachial cuff waveform-derived method with Centron cBP301 
cSBP device.  
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The following research team members will be ‘blinded’ to the blood pressure percentile 
of the patient: (i) technologist/s performing the cardiac and vascular measurements and 
(ii) Research team member entering data to online database ‘MedSciNet’. 
 
6.2.7.1.5. Echocardiography  
2D-guided M-mode echocardiography will be performed using images obtained in either 
parasternal long axis or short axis view of the left ventricle, as recommended by the 
American Society of Echocardiography.224  Echocardiogram studies will be performed 
by trained echocardiographer using a Philips EPIQ ultrasound system at ECLH and 
Philips CX50 at external centres (Philips Inc, Andover, Mass, USA). All studies will be 
stored digitally and analysed by a single investigator who will be blinded to the medical 
history. Left ventricular mass will be calculated using the Devereux equation.225 Left 
ventricular mass varies widely across the paediatric age range, therefore to allow 
standardisation it is usually expressed as left ventricular mass index (LVMI). We will use 
LVMI (LVM divided by height in meters raised to allometric power of 2.7 [g/m2.7]) as a 
measure of LVH that accounts for body size.226 LVH will be defined as LVMI ≥95th 
percentile using age-specific reference intervals for normal children227, where 
appropriate, we will also calculate left ventricular mass for height z-scores.228 Relative 
wall thickness (RWT) will be measured to assess the left ventricular geometry. Patients 
with increased LVMI (≥95th percentile) and elevated RWT (≥0.41), have concentric 
LVH; with increased LVMI (≥95th percentile) and normal RWT (<0.41) have eccentric 
LVH; and those with normal LVMI (<95th percentile) and elevated RWT (≥0.41) have 
concentric remodelling. Shortening fraction will be calculated to estimate the LV systolic 
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function. Diastolic function will be assessed by pulsed Doppler interrogation of mitral 
valve inflow and tissue velocity imaging interrogation at the level of the mitral valve 
annulus both at the septum and left ventricular free wall.229 The mitral valve E/e’ ratio 
will be used as a surrogate for filling pressures. Cross sectional images in both four 
chambers and multiple short axis views will be obtained to permit analysis of myocardial 
rotation and torsion using two dimensional strain (“speckle tracking”) techniques. 
 
6.2.7.1.6. Carotid intima-media thickness  
High resolution ultrasound [Linear transducer for EPIQ and CX50 (15-6MHz)] will be 
used to obtain images of the common carotid artery. Mean common carotid intima-
media thickness (cIMT) will be assessed using automated software (Medical Imaging 
Applications LLC, Iowa, USA) from digitized images obtained in diastole of the near and 
far walls of the both common carotid arteries 1-2 cm proximal to the flow divider.174,175  
 
6.2.7.1.7. Arterial stiffness  
Arterial stiffness will be determined in all subjects by measuring carotid-femoral pulse 
wave velocity (PWVcf) and by measuring brachial-femoral PWV (PWVbf). All 
assessments will be performed by a core group of researchers from the central team 
from ELCH, by visiting each site. Carotid-femoral PWV will be determined using the 
SphygmoCor system (Atcor medical, Australia) in which ECG referenced sequential 
carotid and femoral applanation tonometry is performed. An alternative technique 
(Vicorder, Skidmore Medical) employs simultaneous measurement of pulse waveforms 
from pressure cuffs placed around the arm and thigh. This method is particularly well 
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tolerated in children. The clinical team will be blinded to results of echocardiogram and 
vascular studies. 
6.2.7.2. Assessments at 4-monthly intervals  
The following will be performed 4-monthly in all randomised subjects once their BP level 
is to target as per assignment to randomization arm.  
6.2.7.2.1. Clinical characteristics, examination and anthropomometry  
Recent medical history will be updated and medication review performed. A clinical 
examination will be performed. Height (stadiometer), weight and BMI will be recorded.  
 
6.2.7.2.2. Peripheral blood pressure – clinic blood pressure 
Peripheral BP will be taken as the mean of 3 measurements using appropriate sized 
cuff and a calibrated aneroid instrument according to British Hypertension Society 
guidelines. Systolic BP level will be confirmed to be to study target for each subject but 
if not changes to medication made as appropriate and earlier review performed as per 
suggested schema in Figure 38.  
 
6.2.7.3. All clinic visits 
At all visits compliance with medications will be checked for and any reported missed 




6.2.8. Trial schema and study visit schedule 
All subjects will undergo comprehensive assessment at the baseline visit, following 
which they will be randomized and if clinic systolic BP is to target be seen at least 4-
monthly for the duration of the trial. If clinic systolic BP is not to target they will be seen 
more frequently as suggested in Figure 38. All subjects will undergo study related 
assessments at annual intervals and these will be performed by a core-group of 
research investigators. The information captured at the baseline and subsequent annual 
visits is shown in Table 18. 
 
Table 18: Trial schedule for study procedures and assessments 
 Baseline 1 year 2 year 
Informed consent √   
Allocation of study number √   
Randomisation (post-recruitment) √   
Medical review and physical examination √ √ √ 
Anthropometry √ √ √ 
Medication review √ √ √ 
Peripheral clinic BP measurement
+
 √ √ √ 
Central BP evaluation √ √ √ 
24-hour ABPM (optional)
†
 √ √ √ 
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 Baseline 1 year 2 year 




) √ √ √ 
Echocardiography √ √ √ 
Urine sample √ √ √ 
Blood sample √ √ √ 
+
BP, blood pressure; 
†
ABPM, ambulatory BP monitoring; 
‡
cIMT, carotid intima-medial thickness; 
*
PWV, 
pulse wave velocity 
 
Data will be entered on a trial specific database using an online data entry platform 
‘MedSciNet’. This will be overseen by Mr Bola Coker, at the Biomedical Research 
Centre at King’s Health Partners and Professor Janet Peacock, Trial Statistician. Mr 
Coker will also help with the safe running of study database and collation of results. 
 
6.2.9. Subject retention 
This visit schedule is in keeping with the frequency of routine follow-up of children with 
moderate to severe CKD. Subjects and their families will be updated with study 
progress at the time of any clinic attendances. Clinical teams will also be regularly 
updated with study progress and this will additionally help update the participants and 
therefore maintain subject retention to the trial. All subjects will be provided with contact 




6.2.10. Sample size and power calculation 
A total of 300 subjects will be recruited to the study to include 150 to randomise (75 in 
each trial arm) and 150 as control subjects.  
Differences in outcome will be estimated using a random effects (mixed) model that 
includes the baseline value of the outcome. Sensitivity analyses will be performed to 
also include key prognostic variables including known factors other than blood pressure 
and those identified by univariate analyses. The outcome data are longitudinal and so a 
model that takes account of this data structure will be fitted. The random effects model 
is a 2-level multilevel model that allows for the repeated data within subjects, while 
allowing some measurements to be missing. (This is preferred to repeated measures 
analysis of variance that requires complete data on all subjects). For a particular 
outcome, eg LV mass, the baseline value for each subject will be included in the model 
to adjust for (random) baseline variability between subjects. The results of the analysis 
are in the form of mean difference in LV mass between the intervention and control 
groups, at the endpoint, with a 95% CI. 
The original sample size calculations were based upon longitudinal measurements of 
LVMI at annual intervals in our cohort of children with CKD (n=47). The standard 
deviation (SD) of change in LVMI was 7.7 g/m2.7 and this was obtained without the 
same standardized reading of LVM proposed in this study. To be conservative we 
assume a 20% improvement on our existing data giving an SD of 6g/m2.7 result from our 
own cohort. Thus with n=60 in each group we should be able to detect a difference in 
change in LVMI of > 3.1 g/m2.7 (=9% of baseline LVMI) over the 2 year duration with 
90% power (P<0.05). This is one third of the difference (9.4 g/m2.7) between subjects in 
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our cohort that have blood pressure in the 50-75th and below 40th percentiles. Although 
we are assuming relatively rapid tracking of LV mass in relation to blood pressure, this 
is not unreasonable given the time frame of LV regression in adults. A recent meta-
analysis of randomized studies shows a mean change in LVMI of 10.3% over duration 
of 6 months.230  
Interim analysis will be performed at 1-year by the statistical team to check if the SD of 
LVMI  is in keeping with initial projections. The choice of SD for the initial sample size 
was made using the best data available at the time of the study design. In accordance 
with good practice, we will monitor the SD during the study across the whole study 
group i.e. NOT by randomised group. In this way we can verify that the overall SD 
observed in the trial is in fact as expected. If the SD is found to be very different, either 
larger or smaller, we will consider whether the sample size calculations need to be 
revised accordingly. In this way we will be able to be as certain as is possible that the 
trial is powered as planned and ensure that the primary study endpoint is achieved We 
will inform the Research Ethics Committee of the results of the interim analysis. 
With regard to PWV, the within subject SD for measurements separated by several 
months is 0.5 m/s so we should be able to detect a difference in change in PWV of 0.3 
m/s. Although we do not have data relating PWV to level of blood pressure, this 
difference is small in absolute terms (being equivalent to only a few years of “vascular 
ageing” in adults) and therefore we feel it is likely that we will be able to detect a 




6.2.11. Trial Outcome measures 
The primary outcome measure for the controlled trial will be the differences in LV mass 
between aggressive and standard arms. The secondary outcome measures are the 
difference in carotid IMT and PWV between the aggressive and standard trial arms. 
 
6.2.12. Statistical analysis 
Differences in outcome will be estimated using a random effects (mixed) model that 
includes the baseline value of the outcome. Sensitivity analyses will be performed to 
also include key prognostic variables including known factors other than blood pressure 
and those identified by univariate analyses. An interim analysis at 1-year following 
commencement of study will allow detailed statistical analysis plan to be developed. 
Both SPSSv17 and SigmaStat v10 will be used for statistical analysis, in close 
consultation with statisticians at Kings College London. 
 
6.2.13. Reporting of adverse events 
Adverse events will be assessed at each study visit and data regarding these completed 
in case report forms. Related and unexpected Serious Adverse Events (SAE’s) will be 








6.2.14.1. Trial steering committee 
This committee will comprise of Chief Investigator (Manish Sinha), at-least one of other 
co-applicants (John Simpson, Louise Watt and Professor Phil Chowienczyk), Research 
Nurse (TBA), Research Associate (Haotian Gu and Laura Milne), trial co-ordinator 
(Humra Chadwick) and trial statistician (Professor Janet Peacock). The committee will 
meet regularly to monitor recruitment and completion of study objectives with formal 
meetings annually to monitor data quality, safety and achievement of study objectives. 
 
6.2.14.2. Independent data monitoring committee 
An independent Data Monitoring Committee (DMC) will be established for this trial and 
will include members as per standard guidelines and include at least one member from 
each of the following designations: a statistician, an expert in renal disease and an 
expert in cardiovascular medicine. The DMC will aim to meet annually to review all 
collected data and may meet more frequently if required after analysis of the available 
data. The DMC will advise the Trial Steering Committee on the safety of continuing this 







6.2.15. Regulatory aspects 
The HOT-KID study is sponsored by the Guy’s & St Thomas’ NHS Foundation 
Hospital’s NHS Trust. The ISRCTN number for the trial is 25006406 and the UKCRN ID 
is 12925. This clinical trial will be conducted in accordance with the ethical principles as 
per the Declaration of Helsinki, and the principles of Good Clinical Practice and all 
applicable requirements as stated in the R&D approval.  
 
6.2.16. Ethical committee approval 
The Ethics for this study have been approved by the NRES Committee London – 
Westminster (REC reference 10/H0802/13). All protocol amendments will be submitted 
for approval to the REC before implementation and progress reports and copy of final 
study report will be provided to REC as per standard requirements.  
Ethics approval letter for the HOT-KID trial as Appendix A and example of ‘Parent 




6.3.1. Potential impact 
Heart disease in this population is an important clinical problem. Our knowledge of its 
evolution remains rudimentary with a striking deficiency of studies examining ‘cause and 
effect’. There is complete consensus by experts within the community that the optimal 
treatment target for blood pressure is of key importance. Whilst the multicentre, Effect of 
178 
 
Strict Blood Pressure Control and ACE Inhibition on the Progression of CRF in Pediatric 
Patients (ESCAPE) study158, aimed to evaluate the renoprotective efficacy of intensified 
blood pressure control in paediatric patients with pre-dialysis CKD, has provided some 
data to support a target below the 75th centile (that now proposed as “standard 
treatment” in the present trial), this target is still high compared to that used in the adult 
population. The present study would provide definitive data to support a lower target. 
This project offers a unique opportunity to determine whether a simple intervention that 
could readily be implemented in clinical practice is likely to reduce heart disease. It will 
answer a key translational research question and, if successful, will lay the foundations 
for a large scale multi-centre study which could provide a huge advance in reducing 
adult heart disease in adults with onset of chronic kidney disease (CKD) in childhood. 
This will be of relevance to not only in adults with onset of CKD in childhood but in the 




The study results will be published in accordance with the CONSORT statement and 
SPIRIT guidelines.231,232 Our findings will be submitted to major international paediatric 
nephrology and general paediatric meetings, and submitted for publication in a high 
impact factor journal, with open access. The results will also be communicated 




6.4. Trial status 
As of the 26th October 2015, 240 subjects (including 98 of 150 subjects randomized) 
had been recruited to the study.  The study has been funded by a British Heart 













































Children with chronic kidney disease (CKD) have several fold increased risk of 
cardiovascular (CV) death when compared with the general population both during 
childhood and subsequently as young adults. Through the life-span of their kidneys, 
markers of pre-clinical cardiovascular disease are highly prevalent, often observed to 
progress with worsening renal disease, and are likely to relate to subsequent CV 
morbidity and mortality.19,23,26,28-30,32  
Measures of end organ CV disease in childhood CKD that have been investigated to 
date include arterial stiffness and left ventricular hypertrophy (LVH) and these are often 
associated with several modifiable and non-modifiable CV risk factors.18,36,73 On 
balance, blood pressure (BP) remains one of the main modifiable CV risk factor in 
childhood CKD cohorts, particularly in those with pre-dialysis stages of CKD. Its optimal 
management is likely to improve the risk of future adverse CV outcomes. A substantial 
body of evidence over the past decade, including those from large observational studies 
suggests that uncontrolled BP is both under-recognised and under-treated and that the 
optimal level of BP to improve CV end-organ outcomes in this cohort is not specified.  
Measures of large artery health in children with CKD have been less extensively 
evaluated than in adults. Structural measures such as carotid intima medial thickness 
have been reported but there are limited data regarding pulse wave velocity (PWV) and 
functional measures of arterial health.108-110 Major hurdles include the need for trained 
skilled operators to perform studies on children who have poor tolerance of available 
instruments and methods widely used in adult subjects. An improved evaluation of 
arterial health in children with CKD may lead to a better understanding of CV disease 
and its evolution through childhood to young adulthood. 
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The measurement of PWV in children has been limited due to the lack of techniques 
that are easy to use and well tolerated across the childhood age-range. In chapter III of 
this thesis it is shown that using the Vicorder technique, PWV can be measured easily 
with minimal training and with excellent repeatability, and is well tolerated by most 
children. However, PWV measurements performed using different instruments over the 
same path are not interchangeable.     
To understand the precise role of blood pressure on arterial health it is of course 
imperative to measure the BP in the artery whose stiffness is being evaluated. It is well 
known that systolic BP is amplified along conduit arteries, such that peripheral SBP 
(pSBP) measured at the brachial or radial artery usually exceeds central aortic systolic 
pressure (cSBP) at the aortic root, with little difference between mean arterial pressure 
and diastolic BP. Systolic amplification, the difference between pSBP and cSBP, is a 
result of pressure wave reflection and summation across the arterial tree. In chapter IV 
of this thesis the accuracy of central aortic systolic BP estimated in children using a 
non-invasive method was investigated. Systolic amplification was shown to be 
substantial with a mean amplification of ~20 mmHg, almost twice that seen in adults. 
Future work to understand the factors influencing systolic amplification, impact of 
interventions on peripheral and central systolic BP and if measurement of cSBP offers 
any improved value above pSBP when evaluating the end organ damage in children 
with CKD will be important. 
In chapter V of this thesis we characterised large artery biomechanical properties. In 
this large cross-sectional study of pre-dialysis CKD, we demonstrate the key role of BP 
over other modifiable risk factors. When children with predialysis CKD are compared 
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with healthy children, we show that for the same peripheral and carotid BP anatomical 
and functional elastic properties of the large arteries are comparable but differences in 
functional arterial properties are significant when children with sub-optimal BP control 
(75th percentile) are compared with healthy children. Further, in age, gender and 
peripheral and central BP matched children with and without CKD, we show no 
differences in markers of arterial health. Thus data in this study suggests that although 
functional elastic properties of the carotid artery are some of the earliest identifiable 
biomechanical abnormalities in children with non-dialysis CKD they relate primarily to 
BP and not to level of renal function or markers of mineral bone disease. Important 
limitations to this cross-sectional study include lack of knowledge of duration of both 
hypertension and CKD and lack of power. Despite these limitations, this study suggests 
that effective BP control may be one of the most important ways of protecting children 
with CKD from arterial stiffening and this needs to be evaluated using a controlled 
clinical trial in this cohort.  
In chapter VI of this thesis the protocol of such a controlled clinical trial has been 
presented. The trial is titled, ‘Hypertension Optimal Treatment in Children with Chronic 
Kidney Disease study: The HOT-KID study- a randomised trial to compare effects of 
aggressive versus standard targets in blood pressure on target organ damage in 
children with CKD’ and is designed to provide important definitive evidence whether a 
lower than currently recommended level of clinic blood pressure ameliorates adverse 
cardiovascular target organ outcomes in children with CKD. 
In conclusion, systematic evaluation of arterial health in children remains the missing 
link to a more complete understanding of CV health in this cohort. Improved methods to 
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measure PWV and cSBP will help achieve this objective. Cross-sectional evaluation, in 
those with predialysis CKD suggests that BP is the key modifiable target in this cohort 
and of more significance than mineral bone disease. The ongoing controlled clinical 
trial, the HOT-KID study will determine whether a simple intervention that could readily 
be implemented in clinical practice is likely to reduce the unacceptably high incidence of 
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PARENT INFORMATION SHEET  





The Hypertension Optimal Treatment in Children with Chronic Kidney Disease study: The 
HOT-KID study- A randomised trial to compare effects of aggressive versus standard 
targets in blood pressure on target organ damage in children with CKD 
 
 
A randomised trial is a scientific study used to test how effective a treatment is. It involves 
randomly allocating all the research participants or patients who have agreed to take part, to 
different treatments so that comparisons between the treatments can be fairly made. 
 
Target organ damage – in this sense means possible strain on the heart and arteries caused 
by high blood pressure.  
 
Chronic kidney disease (CKD) – chronic means lasting a long time. You have had this 
condition for a long period and continue to have it now.  
 
Hypertension – this means high blood pressure and is a common complication of chronic 
kidney disease 
 
We would like to invite your child to take part in a research study. Before you decide whether 
you want your child to take part in this study, it is important for you to understand why the 
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research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. Please ask us if there is anything that 
is not clear or if you would like more information. Do take time to decide whether or not you wish 
your child to take part. 
 
What is the purpose of the study? 
Hypertension is a frequent complication in children with chronic kidney disease and can lead to 
strain on the heart causing it to increase in size. It can also lead to strain on the health of the 
tubes carrying blood in the body called arteries and veins. Accurate detection and treatment of 
hypertension in chronic kidney disease is important for the health of the kidneys but perhaps 
also for the health of the heart and arteries. If your child has hypertension they may already be 
on medication to help control this.  
We are comparing two levels of blood pressure to see which is better.The purpose of the study 
is to find out what difference this may make to the overall health of the heart and blood vessels As 
part of the study if your child has chronic kidney disease and hypertension they may need to 
start taking medication or changing the dose of their current medication. 
This study involves more accurate measurement of blood pressure along with assessment of 
the heart and arteries using non-invasive tests such as heart and artery ultrasound. We will also 
assess the health of the arteries by measuring ‘blood vessel stiffness’. We will do this by using 
tests that do not involve any needles. We will also assess the health of your child’s heart and 
kidney by performing tests on blood and urine specimens taken at the time of your routine clinic 
visits. Results from this study will help in improving our understanding of the role of blood 
pressure in chronic kidney disease and benefits of its improved control. Ultimately, this may lead 
to a better understanding of the high rate of heart disease seen in large number of young adults 
who developed chronic kidney disease during childhood.  
 
The proposed duration of this study is 5 years. 
 
Why has your child been chosen to participate in this study? 
You have been invited to participate in the study because your child has got chronic kidney 
disease. To be eligible to participate in this study your child should be older than 2-years of age 
with an estimated kidney function >15% of normal. High blood pressure is a common 
complication of CKD and increases risks of developing heart problems. Your child is also 
eligible to participate in this study even if they have chronic kidney disease and no current 




Your child may also have been invited to participate as they have normal blood pressure and no 
kidney disease but they are coming to the hospital for some other medical reason or their sibling 
has kidney disease or hypertension. Sometimes when doing new tests it is important to know 
what is ‘normal’ so that identifying ‘abnormal’ becomes easier. Your child may have been invited 
to take part in this study as we need to perform studies in ‘normal’ children who do not have 
chronic kidney problems.  
 
We need your permission to perform these tests in either case. 
 
Does your child have to take part? 
Taking part in the study is voluntary. It is up to you and your child to decide whether or not they 
want to take part.  If you do decide to allow your child to take part you will be given this 
information sheet to keep and be requested to sign a consent form. Even if you do consent for 
your child to take part you are still free to withdraw from the study at any time and without giving 
a reason.  We would also want to reassure you that your decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care your child receives at any time. 
 
What will happen to your child once you consent to take part? 
We wish to compare the long term effects on the heart, arteries and kidneys of keeping the 
blood pressure at two different levels. Your child will be allocated into the ‘control’ or 
‘randomised’ group. The control group will have children with CKD and normal blood pressure 
or healthy children. They will not be given any medication. The children in the randomised group 
will be randomly allocated using a special piece of computer software into one of two groups. 
One group will have their blood pressure maintained to that called ‘standard care’ i.e. What the 
current practice for blood pressure control is for patients with CKD. The second group will have 
their blood pressure maintained at a lower level than the first group.  
 
In addition there are seven extra things we would like to do at the time of your child’s routine 
clinic visit and once every 12 months after that for the next 5 years. These tests will not result in 
any extra hospital visits. None of these cause any pain or involve any needles. 
 
1. A detailed ultrasound of the heart and arteries called an ECHO. The ultrasound will be 
performed by experienced technicians who normally work with children. This will take about 
20 minutes and will be performed while you are waiting to be seen by your regular doctors.  
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2. Around the time of the heart ultrasound we would perform a blood vessel stiffness study 
(BVS). This test does not involve any needles and involves light pressure using a pencil-like 
device over one arm, the neck and the groin for 5-10 minutes each. This device also helps 
in measuring central blood pressure. 
    
  
We will also perform blood vessel stiffness study using blood pressure cuffs on the arm, 
thigh and neck to measure the stiffness of the blood vessels. The two methods will take a 
total of 30-40 minutes. This test will be performed in the kidney clinic area by experienced 





    
 
3. Ultrasound of the carotid artery in the neck This is a special ultrasound of an artery in the 
neck and will take 5 minutes.  
 
    
 
 
4. Central blood pressure will be estimated from radial tonometry and modified BP 
measurement using CentronTM BP machine. 
 
5. In some instances if you agree your child may be given a blood pressure 
measurement monitor to use at home. It will measure blood pressure for 24 hours. 
This test will only be performed if your child is over 5 years of age and over 4 feet tall. This 
will record blood pressure measurement twice every hour for 24-hours.  
 
6. Blood sample 5ml (one tea spoonful). This blood will be collected at the same time that 
we take the usual blood tests in clinic. It therefore does not involve extra needles. We plan 
to analyse 2-3 ml of this blood specimen for tests that will measure additional risk factors 
that have an effect on the health of your child’s heart. We will store any additional blood 
specimen for any tests that may become available in the future to detect high blood 
pressure and heart disease.  
 
7. Urine sample: We also require first morning urine specimen (5-10mls each) to be collected 
on three consecutive days prior to a clinic visit once a year and a spot urine sample to be 




How will the study change my child’s treatment? 
This study is designed to test what level of blood pressure control is more beneficial for children 
with chronic kidney disease. If you agree to take part in the study your doctor will assign your 
child randomly to one of two levels of blood pressure control.  
The two levels of blood pressure control are (i) maintaining blood pressure levels at currently 
recommended levels, children assigned to this study ‘arm’ or ‘group’ will be called the ‘standard 
(or higher) blood pressure level treatment group’ and (ii) maintaining blood pressure at lower 
levels than usual, if your child is assigned to this study group they will be included in the ‘lower 
blood pressure level treatment group’.  
We will recommend blood pressure medicines as per this research study to achieve the desired 
blood pressure target to your child’s consultant but it is up to the consultant to decide whether 
this is appropriate for your child or to choose another medicine. Once assigned to a study group 
your child will remain in the same group throughout the duration of the study.   
 
What will happen to your child after the initial investigations have been performed? 
Following the initial set of investigations upon enrolment in the study your child will have all the 
investigations repeated at yearly intervals. The study duration is for 5-years. Participation in the 
research does not mean that your child will need to attend clinic appointments in the hospital 
more often than they have been previously doing.  
 
What do I have to do? 
As a participant you agree to encourage your child to complete the proposed tests if he/she is 
happy to participate. Your child should continue to take all prescribed medications as advised.  
 
What is the drug that is being tested? 
We are not testing any new drugs in this study but we are using standard blood pressure 
medicines in a different way.  
 
What are the side effects of any treatment received when taking part? 
 
More children in the low blood pressure group may need to take medicines or take their current 
medicines at higher doses. This may lead to more side effects. It is possible, if your child is in 
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the group with lower blood pressure targets, that they may have side effects such as generally 
feeling tired or headaches. Parents of children who have occasionally had these side effects 
have observed that their child has less energy than usual or complaints of feeling more tired and 
sleepy through the day. They may also complain of dull headaches. If this happens or you are 
concerned because of any new symptoms in your child please contact us so that we can give 
you advice. If your consultant believes that the lower blood pressure levels may be causing you 
to feel unwell we will stop the additional blood pressure medicine. If participation in the study 
shows that your child has high blood pressure then they will receive appropriate treatment. All 
changes to your child’s treatment will be made after discussing the results of tests with you.   
It may be that we are unable to collect the proposed volume of blood at a particular study. If this 
happens we will attempt to work with the volume of blood obtained or obtain additional samples 
at future clinic visits. If your child feels unwell during the blood test we will stop taking any blood 
at the time.  
 
What are the possible benefits of taking part? 
There are no direct benefits to your child. This study may eventually help us to identify what 
level of high blood pressure is optimal in children with chronic kidney disease. This may help to 
reduce heart disease arising from the strain that high blood pressure can put on the heart.   
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available about 
the disease/technique that is being studied.  If this happens, your doctor will tell you about it and 
discuss with you whether you want your child to continue in the study.  If you decide to withdraw 
your child from the study this decision will not affect the quality of your child’s care.  If you 
decide to continue in the study you will be asked to sign an updated consent form. 
Sometimes, on receiving new information your research doctor might consider it to be in your 
best interests to withdraw your child from the study.  She/he will explain the reasons and 
arrange for their care to continue. 
 
What happens when the research study stops? 
When the research study stops your child will continue to be seen and managed by their 
consultant as required. Any important results that are available before the completion of the 
research study will be known to your doctor.  
 
What if something goes wrong? 
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If there is any harm to your child as a result of taking part in this research project, there are no 
special compensation arrangements. If your child is harmed due to someone’s negligence, then 
you may have grounds for a legal action. Regardless of this, if you wish to complain, or have 
any concerns about any aspect of the way you or your child have been approached or treated 
during the course of this study, the normal National Health Service complaints mechanisms will 
be available to you. 
This study is sponsored by the Guy’s and St Thomas’ NHS Foundation Trust. The sponsors will 
at all times maintain adequate insurance in relation to the study independently. The Trust has a 
duty of care to patients via NHS indemnity cover in respect of any claims arising as a result of 
clinical negligence by its employees, brought by or on behalf of a study patient. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about your child during the course of the research will be kept strictly 
confidential.  Any information about your child that leaves the hospital will have their name and address 
removed so that they cannot be recognised from it. We will inform your GP that your child is 
participating in the research study. 
 
We have made sure that all the other parties participating in the study are aware of the laws and 
regulations that protect patient confidentiality. (These regulations include the Data Protection 
Act 1998 and similar legislations in other EU countries.) Under this protection, only authorized 
representatives connected with research are permitted access to names and other identifying 
characteristics.  If we need somebody else to access your identification we will ask this 
permission from you in writing. 
 
What will happen to the results of the research study? 
The findings of the research study will be published in peer-reviewed journals and discussed at 
scientific meetings. It is likely that results of the research will be reported annually and at the 
end of the study. Copies of the published results could be obtained from your doctors. Any 
reports or publications will be anonymised for any patient details. This will ensure that the 
identity of your child is not revealed.  
 
Who is organising and funding the research? 
 
This research study has been generously funded by the British Heart Foundation. The nurses 





Who has reviewed the study? 
The ethics for this study has been reviewed and approved by the St Thomas’ Hospital Research 
Ethics Committee now called the NRES Committee London - Westminster. They make sure that 
the research is fair and ethical in its treatment of your child as a research participant. 
 
Contact for further Information 
 
Please discuss any questions you may have with your trial doctor or members of the research 
team: 
Your trial doctor is:    
Name:      Contact phone number: 
Your research/specialist nurse is:  
Name:      Contact phone number: 
 
You will be given a copy of the information sheet and a signed form to keep.  
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